IL-32 producing CD8⁺ memory T cells and Tregs define the IDO1 / PD-L1 niche in human cutaneous leishmaniasis skin lesions.

Nidhi S. Dey¹, Shoumit Dey¹, Naj Brown¹, Sujai Senarathne², Luiza Campos Reis^{3,¥}, Ritika

Sengupta⁴, Jose Angelo L. Lindoso^{5,6}, Sally James⁷, Lesley Gilbert⁷, Mitali Chatterjee⁴, Hiro

Goto³, Shalindra Ranasinghe² and Paul M. Kaye^{1*}

3

4

5

6

7 ¹York Biomedical Research Institute, Hull York Medical School, University of York, UK. 8 ²Department of Parasitology, Faculty of Medical Sciences, 9 University of Sri Jayewardenepura, Sri Lanka. 10 11 ³Department of Preventive Medicine, Instituto de Medicina Tropical de São Paulo, Faculdade 12 de Medicina, Universidade de São Paulo, Brazil. ⁴Department of Pharmacology, Institute of Postgraduate Medical Education and Research, 13 Kolkata, India. 14 ⁵Secretaria de Saúde do Estado de São Paulo, Instituto de Infectologia Emílio Ribas, São 15 Paulo, SP, Brasil 16 ⁶University of São Paulo, Faculty of Medicine, Department of Infectious and Parasitic 17 Diseases, São Paulo, SP, Brazil. 18 ⁷Technology Facility, Department of Biology, University of York, York, YO10 5DD 19 20 *Correspondence: Paul M. Kaye, paul.kaye@york.ac.uk 21

- 22
- 23 [¥] Current address: Escuela Profesional de Medicina Humana, Facultad de Medicina,
- 24 Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas, Chachapoyas, Peru.
- 25

- 26 Key words: Human cutaneous leishmaniasis, Host directed therapy, skin, IL-32, CD8
- 27 memory T cells, Regulatory T cells, Prognosis, Spatial Transcriptomics, IDO1, PD-L1,
- 28 myeloid cells.
- 29 Total words = 4371 (excluding methods, abstract, figure legends and references)

31 Abstract

32 Human cutaneous leishmaniasis (CL) is characterised by chronic skin pathology.

- 33 Experimental and clinical data suggest that immune checkpoints (ICs) play a crucial role in
- 34 disease outcome but the cellular and molecular niches that facilitate IC expression during
- 35 leishmaniasis are ill-defined. We previously showed that in Sri Lankan patients with CL,
- indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) are enriched
- 37 in lesion skin and that reduced PD-L1 expression early after treatment onset predicted cure
- rate following antimonial therapy. Here, we use spatial cell interaction mapping to identify
- 39 IL-32-expressing CD8⁺ memory cells and regulatory T cells as key components of the IDO1 /
- 40 PD-L1 niche in Sri Lankan CL patients and in patients with distinct forms of dermal
- 41 leishmaniasis in Brazil and India. Furthermore, the abundance of IL-32⁺ cells and IL-
- 42 $32^{+}CD8^{+}T$ cells at treatment onset was prognostic for rate of cure in Sri Lankan patients.
- 43 This study provides a unique spatial perspective on the mechanisms underpinning IC
- 44 expression during CL and a novel route to identify additional biomarkers of treatment
- 45 response.

47 Graphical Abstract

48



50 Introduction

51	Cutaneous leishmaniasis (CL) is caused by protozoan parasites of the genus Leishmania and
52	exhibits a wide spectrum of clinical presentations determined at least in part by the host
53	immune response. Leishmania are intracellular parasites of myeloid cells, predominantly
54	macrophages, monocytes, and dendritic cells ^{1, 2, 3} . Consequently, protective immunity is
55	largely cell-mediated, with effector CD4^+ and CD8^+ T cells producing cytokines (e.g. IFN γ)
56	that activate myeloid cell-intrinsic leishmanicidal activity ^{4, 5} . Over-exuberant or persistent
57	effector T cell function at the site of infection can lead to tissue damage and progression of
58	clinical disease despite a reduction in parasite load ^{6.} Conversely, parasite persistence has
59	been attributed to a combination of dysregulation of the T cell response and parasite-
60	mediated subversion of epigenetic and transcriptional pathways that control macrophage
61	polarisation and activation ⁷ .

62

Studies in animal models have elegantly demonstrated the impact of dichotomy in CD4⁺T 63 cell responses to *Leishmania*. For example, enhanced CD4⁺ Th2 responses ⁸ are responsible 64 for the genetically determined susceptibility of BALB/c mice to L. major infection and IL-4-65 driven alternatively activated macrophages favour parasite survival⁹. This dichotomy in 66 67 CD4⁺ T cell response has some parallels in human leishmaniasis. Strong Th1 responses are associated with resolution of infection in CL patients infected with L. donovani in Sri Lanka⁹ 68 and with *L. major* in Iran¹⁰, whereas increased lesional IL-4 was observed in Sri Lankan 69 patients with a poor response to treatment ¹¹. However, chronic stimulation of CD4⁺ Th1 70 cells leads to differentiation into Tr1 cells producing IL-10, a well-known inhibitor of IFNy-71 mediated NO production ¹². Regulatory T cells producing IL-10 have also been associated 72 with parasite latency, treatment resistance, and disease relapse in humans $^{13, 14}$. In L. 73 74 braziliensis infection, chronic lesion development occurs in the face of relatively low parasite

⁷⁵ burden and has been most commonly associated with an over-exuberant cytolytic CD8⁺ T
⁷⁶ cell response ¹⁵.

77

In leishmaniasis ¹⁶ as well as many other infectious ¹⁷ and non-infectious ^{18, 19} diseases, the 78 79 role of immune checkpoints (ICs) as regulators of T cell effector function and disease 80 outcome has been well described. For example, indoleamine-2,3-dioxygenase (IDO1) is a 81 metabolic IC molecule expressed in response to inflammatory insults by macrophages 20 , dendritic cells ²¹ and B cells ²² and catalyses degradation of tryptophan ²³. Tryptophan 82 starvation in T cells leads to proliferation arrest ²³, anergy ²⁴ or regulatory phenotypes ²⁵. 83 facilitating tumour immune escape ²⁶ or in the case of CL lesion progression ²⁷. Similarly, 84 85 programmed death ligand 1 (PD-L1; CD274) is expressed by myeloid cells upon activation 86 via LPS/IFN- γ or IL-4 and when bound to PD-1 on T cells inhibits activation and promotes IL-10 expression 28 . These and other ICs have become invaluable prognostic and therapeutic 87 88 targets in cancer. Co-expression of PD-L1 and IDO1 in resected non-small cell lung cancer (NSCLC) may predict survival outcome ²⁹ and triple blockade of IDO1, PD-L1 and 89 MAPK/ERK kinase has been proposed as therapy in NSCLC³⁰. In a similar vein, an 90 91 immunomodulatory vaccine targeting IDO1⁺PD-L1⁺ myeloid cells is under development for metastatic melanoma³¹. In addition to modulating the natural course of disease, ICs may 92 93 also play a role in tempering the efficacy of conventional but immune-dependent anti-94 infectives and anti-cancer drugs. For example, we recently demonstrated that PD-L1 and 95 IDO1 are enriched in skin lesions of CL patients in Sri Lanka and that a decrease in PD-L1 96 expression early after treatment onset was predictive of rate of cure following treatment with 97 sodium stibogluconate, a well-known immune dependent drug ³². Despite many examples of disease-associated aberrant expression of IDO1 and PD-L1^{33, 34, 35,} 98 ^{36, 37, 38}, our understanding of the cellular and molecular pathways that regulate expression of 99

100	the ICs is largely derived from in vitro studies. Multiple cytokines and inflammatory signals
101	can induce IDO1 $^{39, 40}$ and PD-L1 $^{41, 42}$ expression on human monocytes and DCs, including
102	IFNγ, TNF, TGF-β, IL-6, IL-10, IL-27, IL-32, PAMPs/DAMPs, and PGE2. IDO1 and PD-
103	L1 are also induced by intracellular infection with <i>Leishmania</i> ^{32, 43, 44} and other pathogens ^{45,}
104	⁴⁶ suggesting that subversion of host cell function by manipulation of ICs is a conserved
105	mechanism across pathogen evolution. There is currently little understanding, however, of
106	how these ICs are regulated in the complex spatial microenvironments associated with
107	chronic tissue pathology that result from either infection or cancer.
108	
109	Here, we have combined multiple spatial methodologies to define the cellular and
110	transcriptomic composition of niches containing IDO1 ⁺ and PD-L1 ⁺ myeloid cells in tissue
111	biopsies from Sri Lankan CL patients and patients with other diverse forms of dermal
112	leishmaniasis. Our results reveal diversity in niche composition and localisation, but identify
113	IL-32 ⁺ CD8 ⁺ T cells and IL-32 ⁺ Tregs as common attributes of these immunoregulatory
114	microenvironments.
115	
116	Results
117	CD274 and IDO1 localise to myeloid cell-rich niches
118	To understand the cellular and molecular architecture of human CL lesions, we conducted
119	Visium spatial transcriptomics on FFPE sections from 6 patients (P1-P6; Supplementary
120	Table 1) presenting with a papular and/or ulcerative plaque lesion typical of Sri Lankan CL

121 (SL_CL) (**Fig.1a** and **Extended Data Fig.1a**). H&E staining and immunochemistry revealed

- dense cellular infiltration and parasitism in the papillary dermis (Fig.1b and Extended Data
- 123 Fig.1b). A total of 2418 Visium spots (median of 4104 gene counts per spot; Extended Data
- 124 Fig.1c) were coloured by cluster identities and visualised in UMAP space, with

125	representation from all 6 patients in each cluster (Fig.1c). 11 high level clusters were
126	identified and annotated namely My1, My2 and My3 (Myeloid rich), B/Fib (cluster rich in B
127	and Fibroblast transcripts), TL (T lymphocyte rich), KC1 (Keratinocyte 1 rich), Fib
128	(Fibroblast 1 rich), KC2 (Keratinocyte 2 rich), B (B cell rich), and Endo (Endothelial cell
129	rich) and an uncharacterised cluster (mix) (Fig. 1d,e). Spatial mapping generated a coarse
130	transcriptomic map reflecting underlying tissue morphology (Fig. 1f and Extended Data Fig.
131	1b,d). The three myeloid rich clusters had distinct positioning and gene expression
132	signatures. My1 (SELENOP+) and My2 (CCL18 ⁺) were located in the papillary dermis near
133	the epidermal-dermal junction (herein referred to as "lesion core"), My1 also contained B
134	cells (IGHA1, IGHG2, IGKC) (Supplementary Fig. 1a). My1 and My2 were enriched for
135	mRNAs encoding i) S100 proteins (S100A8, S100A9) suggestive of neutrophils, monocytes
136	and DC ⁴⁷ ; ii) metallothionein genes (MT1H, MT1G, MT1X and MT2A) and SLC39A8,
137	suggesting altered metal ion homeostasis; and iii) CCL18, a T cell chemoattractant ⁴⁸
138	(Supplementary Fig. 1b). My3 (<i>CHIT1</i> ⁺) was associated with a T lymphocyte-rich cluster
139	(CCL19 ⁺) deeper in the dermis (Extended Data Fig. 1d). IDO1 and CD274 transcripts
140	mapped to the lesion core and to the T cell rich region (Fig. 1g,h, and Supplementary Fig.
141	2a,b) and to the My1, My2 and My3 clusters (Fig. 1i). My2 was also enriched for other
142	immune regulators including SIGLEC10 ⁴⁹ , VSIG4 ⁵⁰ and CD300E ⁵¹ (Supplementary Fig.
143	1b).

144

Using a publicly available scRNAseq dataset³⁸ and the Cell2Location⁵² prediction tool, we
projected estimated abundances of 40 cell types (Extended Data Fig. 2). Although some
interpatient heterogeneity was observed, macrophages (*FCGR2A*, *F13A1*, *NR4A1*, *NR4A2*, *KLF4*), helper T cells (*CD4*, *IL7R*, *CD40LG*, *PTGER4*), regulatory T cells (*FOXP3*, *TIGIT*, *BATF*, *CTLA4*), natural killer cells (*KLRD1*, *GNLY*, *PRF1*, *GZMB*, *NKG7*), and cytotoxic T

150	cells (CD8A	, CD8B) were most	highly re	presented.	(Extended	Data Fi	g. 2a). M [•]	y1,	My	/2
-----	-------------	--------	-------------	-----------	------------	-----------	---------	-------	-------------------	-----	----	----

- and My3 clusters contained Tc, Th, Treg and NK cells, myeloid DC (DC2; *CD68*, *NR4A1*,
- 152 NR4A2, CLEC10A, FCGR2A, CD83^{low}), ILC2 (IL7R, PTGDR2, GATA3), Macro1(MARCO,
- 153 CD163, C1QB, FCGR2A), Macro2, monocytes (CD14, 1L1B) and ILC1/NK (KLRB1, XCL1,
- 154 XCL2, TNFRSF18, TNFRSF11, FCER1G, KIT) in differing proportions (Extended Data Fig.
- 155 **2b-l**). Although Ig transcripts were found in these clusters, formal identification of B cells /
- plasma cells was not possible using the Reynolds et al reference data set 38 .

157

158 Mature dendritic cells express abundant CD274 and IDO1 mRNA

- 159 To overcome limitations of cellular deconvolution, we next applied single cell spatial
- transcriptomics. Using Nanostring $CosMx^{53}$, we analyzed 115,157 single cells from 20 fields
- 161 of view (FOVs) derived from four patients (**P3-P6**; **Extended Data Fig. 3a-e**)
- 162 (Supplementary Table 1) and identified 22 cell clusters (Fig.2a and Extended Data Fig.

163 **3f,g**). Cells with myeloid signatures were most abundant in the papillary dermis (**Fig. 2b**),

supporting our Visium analysis. We also identified T cells near the dermal and epidermal

boundary, flanked by fibroblasts and B cells in the lesion core. Deeper in the dermis, T cells

along with scattered macrophages were dominant (Fig.2b). The localisation of additional cell

167 populations is shown in **Extended Data Fig. 4a-d**. We next subclustered all myeloid cells

168 (mac, mac2, mDC, pDC, monocytes, and neutrophils) to obtain 13 sub-populations (Fig. 2c,d

and **Extended Data Fig. 4e,h**). When ranked by *CD274* and *IDO1* mRNA abundance

170 (Extended Data Fig. 4i,j), mature dendritic cell cluster DC3 was identified as having the

171 highest proportion of *IDO1*^{hi} *CD274*^{hi} cells. Smaller proportions of many other myeloid cell

populations also expressed these ICs. DC3 mapped to the lesion core and the deeper T cell

173 rich regions of the dermis (Fig.2e) and expressed mRNA for other immunoregulatory

174 molecules (*CD40* and *PDCD1LG2*; PD-L2; **Fig. 2d**).

175 CD274 and IDO1 mRNA abundance correlates with distinct cytokines and chemokines

- 176 To gain insights into the pathways leading to IDO1 and PD-L1 expression, we first sought to
- identify cytokine expression in niches where $CD274^+$ and $IDO1^+$ cells were abundant. Due to
- the limited cytokine / chemokine coverage of the CosMx gene panel, we reverted for this
- analysis to our Visium data. We classified Visium spots into four classes: *CD274^{hi}ID01^{lo}*
- 180 (CD274 spots), *CD274^{lo}IDO1^{hi}* (IDO1 spots), *CD274^{hi}IDO1^{hi}* (IDO1/CD274 spots) or
- 181 $CD274^{lo} IDO1^{lo}$ (rest of the spots) and mapped their distributions and predicted cell type
- abundances (Fig. 3a,b and Extended Data Fig. 5a-d)). As compared to CD274 spots,
- 183 IDO1/CD274 spots and IDO1 spots had a higher monocyte abundance and higher cytotoxic T
- 184 cell : helper T cell ratio. We performed differential expression analysis to identify cytokines,
- 185 chemokines, their receptors, and ICs that were significantly different across these classes
- 186 (Extended Data Fig. 5e) and observed four distinct patterns of gene expression (Fig. 3c-k
- and Extended Data Fig. 5f,g). CCL18, IL24, IL1B, TNFRSF6B, IFNGR2, CXCL9 and IL32
- 188 were highly expressed in IDO1/CD274 spots and to a lesser degree in IDO1 spots in the
- lesion core, with *CXCL9* and *IL32* also found in the T cell rich hypodermis (**Fig. 3d-g**). The
- 190 homeostatic chemokines *CXCL12*⁵⁴ and *CXCL14*⁵⁵ showed a reciprocal distribution being
- associated with spots lacking *IDO1* and *CD274* (Fig. 3h,i). *CCL19* (Fig. 3j), *CCR7*,
- 192 *CXCL13* and *LTB* (**Fig. 3k**) were most highly expressed in CD274 spots in T cell rich areas.
- 193 Amongst anti-leishmanial effector and regulatory cytokines¹, *TNF* and *IFNG* were mostly
- 194 concentrated in the lesion core while *TGFB1* was widespread across the tissue (Extended
- 195 **Data Fig. 5h-j**).
- 196

197 Neighbourhood analysis of CD274 and IDO1 expressing cells

- 198 To identify cellular interactions contributing to the *CD274* and *IDO1* niches, we similarly
- 199 classified myeloid cells in our CosMx dataset into 4 classes by *IDO1* and *CD274* expression

200	(Fig. 4a,b and Extended Data Fig.6a,b). CCL18 ⁺ macrophages (<i>CCL18</i> , <i>MT2A</i> , <i>CD14</i> ,
201	S100A9, C1QB, CD68, LYZ) were the predominant cell type across all three classes (Fig. 4c
202	and Extended Data 6a,b). We then used Delaunay triangulation in Giotto to construct a pan
203	spatial network based on cell centroid physical distances ⁵⁶ . We observed that each cell had
204	4-8 close "neighbours" (Extended Data Fig. 6c,d). Using this framework, we assigned
205	IDO1 ⁺ mye, CD274 ⁺ mye and IDO1 ⁺ / CD274 ⁺ mye cells as 'source' cells or as "both"
206	neighbour and source (Fig.4d, e and Extended Data Fig.6e,f) and visualised source-
207	neighbour or both-neighbour abundance using the UpSetR tool ⁵⁷ (Fig.4f and Extended Data
208	Fig. 6 g,h). This analysis revealed a consistent neighbourhood composition, comprising other
209	<i>IDO1</i> ⁺ or <i>CD274</i> ⁺ myeloid cells, <i>CD274 IDO1</i> ⁻ <i>CCL18</i> ⁺ macrophages, CD8 memory T cells
210	and regulatory T cells (Tregs) (Fig. 4g-i). For orthogonal validation, we performed
211	immunostaining for PD-L1, IDO1, and CD8 proteins in biopsies where sufficient tissue was
212	available (n=23 SL-CL patients), demonstrating $CD8^+$ T cells in close proximity to IDO1 and
213	PD-L1 positive cells (Fig. 4j). Employing bespoke image analysis pipelines, we created
214	image masks at distances of 25, 50, and 100 microns from IDO1 ⁺ , PD-L1 ⁺ (Extended Data
215	Fig. 6i,j) and $IDO1^+ PD-L1^+$ cells (Fig. 4k), revealing that the majority of $CD8^+ T$ cells were
216	located within $25\mu m$ of such cells and confirming them as immediate neighbours.
217	
218	We then examined the phenotypes of source and neighbouring cells with respect to cytokines

and chemokines identified above as co-enriched in *CD274* and *IDO1* niches (**Fig. 3c**). *IL32*

expression was significantly higher in CD8⁺ T memory cells and Tregs whereas *CXCL9* and

221 *CCL18* were predominantly expressed by other myeloid cells including those that also

expressed CD274 and IDO1 (Fig. 41-n). In contrast, IL24, IFNGR2 and IL1B were primarily

expressed by $IDO1^+$ and $CD274^+$ and source myeloid cells (**Fig 4n-q**). Similar patterns were

observed for neighbours of *CD274* and *IDO1* single positive cells (Extended Data Fig. 6k,l).

225	Hence, in Sri Lankan CL lesions, CD8 ⁺ memory T cells and Tregs (Extended Data Fig. 6m)
226	represent the most common neighbours of $CD274^+ IDO1^+$ cells and are a major source of the
227	<i>CD274-</i> and <i>IDO1-</i> inducing cytokine IL-32. Since both <i>IL32β</i> and <i>IL32γ</i> isoforms can
228	induce either IDO1 or/and PD-L1 in macrophages $^{58, 59, 60}$, and IL-32 γ expression has been
229	reported in patients with L. (V.) braziliensis infection ⁶¹ , we investigated which isoform was
230	expressed in SL_CL lesions. Quantitative RT-PCR confirmed that $IL32\gamma$ and $IL32\beta$ were the
231	most highly upregulated isoforms in lesion compared to healthy skin (Extended Data Fig.
232	7).
233	
234	IL32 is a common spatial correlate of CD274 and IDO1 expression.
235	Although differing mechanisms of immunopathology may occur across the leishmaniasis
236	disease spectrum, IDO1 and PD-L1 have been consistently identified in transcriptomic
237	studies ^{32, 62, 63, 64, 65} . To assess whether the <i>CD274</i> and <i>IDO1</i> niche composition we
238	identified in SL_CL patients was also seen in other forms of dermal leishmaniasis, we
239	performed Visium analysis on biopsies from four Brazilian patients with L. (V.) braziliensis
240	CL (Fig. 5a, b, Extended Data Fig. 8a, b and Supplementary Table 2) and two patients
241	from India with L. donovani post kala-azar dermal leishmaniasis (PKDL) (Fig. 5c,d,
242	Extended Data Fig. 8c, d and Supplementary Table 3). Histologically, we observed a
243	diffuse cellular infiltrate in these samples (Fig. 5b,d and Extended Data Fig. 8b,d), and
244	CD274 and IDO1 expression showed similar patterns within the papillary dermis (Fig. 5e,f
245	and Extended Data Fig. 8e-g). Using the same analysis strategy (Fig. 5g and Extended
246	Data Fig. 8h), we found that <i>IDO1</i> ^{hi} <i>CD274</i> ^{hi} spots were restricted mainly to the upper
247	dermis (Fig. 5h,i and Extended Data Fig. 8i, j). IL32 and CXCL9 were strongly expressed
248	in all IDO1/ CD274 spots in both datasets along with other cytokines (Extended Data Fig.
249	9a-f). Based on the top 50 correlates (top 10 shown in Extended Data Fig. 9g-j), we

250	identified signatures	associated with <i>IDO1</i>	(IL32.	GBP5.	GZMB	LYZ	SOD2	. IFI30.	FTH1.
			·			,		,	

- 251 *GBP1, SRGN, CTSS;* Fig. 5j) and *CD274 (IL32, LYZ, WARS, IF130, FTH1 GBP1, FCER1G;*
- Fig. 5k) expression across all three disease forms. A subset of 5 genes emerged as a core
- correlate across all three datasets, namely IL32, LYZ (Lysozyme), GBP1 (Guanylate-Binding
- 254 Protein 1), *IFI30* (lysosomal thiol reductase) and *FTH1* (Ferritin heavy chain 1).
- 255

256 IL-32 is a predictive biomarker for rate of cure in Sri Lankan CL

As IL-32 has been previously shown to induce IDO1 and PD-L1 expression and the latter has

258 been related to treatment outcome, we investigated the association between IL-32 expression

- and treatment outcome (Fig. 6). Quantitative analysis of IL-32 staining in the dermis (n=25
- 260 SL_CL patients; Fig. 6a and Supplementary Table 1) allowed stratification into two patient
- 261 groups (IL- 32^{hi} or IL- 32^{lo}) based on geomean number of IL- 32^{+} cells / mm² (**Fig. 6b**). IL-
- 262 32^{lo} patients were significantly more likely to cure early after treatment compared to IL-32^{hi}
- patients (Log rank test, p=0.0025; Fig. 6c) with an estimated age- and sex- adjusted Cox
- model hazard ratio of 3.5 (95% CI, 1.19 10.3, p = 0.023; Fig. 6d). Given that our
- neighbourhood analysis above indicated a role for IL-32⁺ Treg cells in maintenance of the
- 266 IDO / PD-L1 niche, we stained tissue sections for IL-32 in combination with a marker of
- 267 Tregs (FoxP3; n=22 patients; **Fig. 6e**). Patients stratified based on FoxP3⁺ IL-32⁺ cell
- abundance (Fig. 6f) did not show a significant difference in cure rate (Fig. 6g,h). In contrast,
- when we conducted a similar analysis based on co-expression of IL-32 and CD8 α (n=25
- 270 patients; **Fig. 6i-l**) we found that patients with low abundance of CD8⁺IL-32⁺ cells were
- significantly more likely to cure earlier (Log rank test, p=0051) with an age- and sex-adjusted
- 272 Cox model hazard ratio of 2.78 (95% CI, 1.093-7.5, p=0.044; Fig. 6k). Collectively, these
- 273 data strongly argue that $IL-32^+CD8^+T$ cells are associated with the generation and / or

maintenance of IDO1 and PD-L1 niches during CL and in such a way indirectly serve torestrain immune-dependent chemotherapy.

276

277 **Discussion**

278 Enrichment of cells expressing IDO1 and PD-L1 is a common feature of chronic inflammatory diseases ^{66, 67, 68, 69, 70} and cancer ^{40, 71}, underscoring the role of myeloid-T cell 279 280 interactions in pathological tissue microenvironments. High-throughput spatial profiling 281 studies have revealed immunosuppressive niches in cancer tissue microenvironments 282 (TMEs), comprising IDO1- and PD-L1- expressing suppressive macrophages, CD8⁺ T cells and regulatory T cells^{33, 66, 72}. Two studies also shed light on the regulators of IDO1 and PD-283 284 L1 in the tumour microenvironment. One used multiplexed imaging to show IFN γ -dependent increases in $CD4^+/CD8^+$ T cells in *ex vivo* "responder" tumour explants ⁶⁶. The second used 285 286 limited protein/chemokine panels to characterize dysfunctional CD8⁺ T cells in melanomaassociated tertiary lymphoid structures ⁷³. In our current study of CL lesions, we applied i) 287 288 whole transcriptome-based spatial analysis to identify different cytokines and chemokines 289 associated with IDO1 and PD-L1 microenvironments, ii) a targeted subcellular 1000-plex 290 RNA panel to reveal cellular interactions at single cell resolution, and iii) validated our 291 results using quantitative immunohistochemistry. 292



identified myeloid cell-rich niches comprising mature dendritic cells (DC3) and CCL18⁺ M2-

like macrophages (CCL18_mac) in the papillary dermis that highly express *CD274* (PD-L1)

and *IDO1*. Second, neighbourhood analysis identified close interactions between

297 $CD274^+/IDO1^+$ myeloid cells, and CD8⁺ memory T cells and Tregs as well as with $IDO1^-$

298 CD274 CCL18⁺ macrophages. Third, we identified a molecular signature associated with

299	these niches (CCL18, IL24, IL1B, TNFRSF6B, IFNGR2, CXCL9 and IL32) and their cellular
300	source. Finally, using other geographically and clinically diverse forms of dermal
301	leishmaniasis, we narrowed this signature to 5 common correlates of IDO1 and CD274 (IL32,
302	<i>LYZ</i> , <i>GBP1</i> , <i>IFI30</i> and <i>FTH1</i>). While both GBP1 ⁷⁴ and FTH1 ⁷⁵ have garnered interest as
303	therapeutic targets in cancer and inflammation, IL-32 emerged as a key factor produced by
304	CD8 ⁺ T memory and Treg cells in our study. High abundance of IL-32 ⁺ CD8 ⁺ T cells
305	correlated with slower healing in Sri Lankan patients treated with sodium stibogluconate,
306	identifying it as a prognostic biomarker for treatment response in this form of leishmaniasis.
307	Hence, this study provides new insight into mechanisms supporting the generation of
308	immunosuppressive niches in CL lesions and reveals cell interactions and gene signatures
309	that may impact treatment response (as shown here) or disease natural history.
310	
311	Myeloid cells play a central role in the immunobiology of leishmaniasis and have been
312	explored extensively in mouse models, with studies ranging from seminal studies of
313	migratory skin DCs ⁷⁶ to the more recent identification of embryonic-derived CD206 ^{hi}
314	macrophages ⁷⁷ and inflammatory monocytes ⁷⁸ as preferred host cells for <i>L. major</i> . Myeloid
315	cell heterogeneity in the context of human leishmaniasis is much less well-understood and
316	our analysis formally demonstrates the complexity of the myeloid cell response in terms of
317	phenotypic heterogeneity and spatial organisation. We highlight two notable findings. First,
318	we find a substantial proportion of moDCs and DCs distributed between the lesion core and T
319	cell rich regions in the hypodermis. These DCs expresses IDO1 and CD274 supporting
320	previous observations that DCs with regulatory phenotype are expanded in chronic
321	inflammatory conditions and might contribute to immunosuppression ^{38, 79} . Second, the lesion
322	core contains abundant CCL18-expressing macrophages and these account for a significant
323	fraction of all myeloid cells expressing IDO1 and CD274. CCL18 produced by such

324	macrophages may recruit naïve T cells 80 and Tregs 48 to further augment an inhibitory niche.
325	In an analogous fashion, CCL18 ⁺ tumour associated macrophages (TAMs) promote
326	immunosuppression in cancer ⁸¹ . Furthermore, <i>IDO1⁺ CD274⁺ CCL18⁺</i> macrophages express
327	IL1B, IL24, and IFNGR2. Given previous studies that indicate a role for IFNs in the induction
328	of PD-L1 and IDO1 in macrophages $^{39, 42}$ and for TNF in the induction of IL-24 and IL1B 82
329	these data are suggestive of macrophage activation by both IFN γ and TNF. This conclusion
330	is further supported by co-expression of TNF and IFNG in IDO1/ CD274 spots in the lesion
331	core, associated with T cell infiltration. Thus, in CL the regulation of IC expression appears
332	distinct from that recently described in the IFN γ -depleted core of tuberculosis granulomas ³⁵ .
333	
334	In the tumour microenvironment, macrophages also foster a supportive environment for
335	malignant cell survival through coupled inhibition of apoptosis and compromised
336	immunosurveillance ⁸³ . For example, soluble decoy receptor 3 (<i>TNFRSF6B</i> ; DcR3) inhibits
337	apoptosis by binding to LIGHT ⁸⁴ or Fas-Fas ligand ⁸⁵ complexes on T cells and, through its
338	interaction with heparin sulphate proteoglycans, can also promote epigenetic reprogramming
339	and macrophage polarisation to an M2 phenotype ⁸⁶ . We observed that DcR3 was also
340	expressed in the IDO1 / PD-L1 niches found in CL lesions, suggesting that further
341	exploration of the role of DcR3 in leishmaniasis is warranted.
342	

component of the IDO1 / PD-L1 niche in multiple forms of dermal leishmaniasis. IL-32 is a complex and still poorly understood cytokine that can be produced by multiple cell lineages (reviewed in ⁸⁷). Studies of IL-32 are hampered by multiple isoforms, each with distinct biological effects and the lack of IL-32 in rodents ⁸⁸. IL-32γ is the longest isoform with an intact signal peptide and is secreted. Both IL-32ß and IL-32γ are proinflammatory, with the

349	beta isoform being the most abundant and the gamma isoform being the most biologically
350	active ⁸⁹ . IL-32 has been mooted as a biomarker in a variety of skin conditions including
351	atopic dermatitis and melanoma 90 . It has been ascribed a pro-inflammatory and host
352	protective role in tuberculosis and in models of colitis and arthritis based on the use of
353	huIL32 transgenic mouse models. A role for IL-32 in leishmaniasis has also been previously
354	suggested, based on similar transgenic mouse models and the enhanced expression of IL-32
355	in lesion biopsies from patients with <i>L. braziliensis</i> infection ^{61, 88} . However, none of these
356	published studies has addressed IL-32 expression in a spatially resolved manner. We
357	confirmed high expression of both IL32 γ and IL32 β in our patient biopsies, identified the
358	cellular sources of IL-32 in the lesion, spatially mapped IL-32 and demonstrated that IL- 32^+
359	$\rm CD8^{+}T$ cells represent a key molecular and cellular component of the IDO / PD-L1 niche. In
360	keeping with other facets of IL-32 biology, our data imply a microenvironmentally-controlled
361	immunoregulatory role for IL-32 in human CL.
362	

363 Despite the differences in pathologies between SL_CL, L. braziliensis CL and PKDL, our analysis revealed a core gene signature (IL32, LYZ, GBP1, IFI30 and FTH1) associated with 364 365 $IDO1^+$ and $CD274^+$ expression. IL-32 expression is commonly associated with T cells and 366 especially Tregs, though we demonstrate that this cytokine can also be expressed at low 367 frequency in some myeloid cells in CL lesions. In contrast, LYZ (lysozyme), GBP1 368 (Guanylate-Binding Protein 1, an interferon inducible GTPase), *IFI30* (Interferon inducible 369 lysosomal thiol reductase) and FTH1 (Ferritin heavy chain 1) are all prototypic myeloid cell 370 markers. This mixed cellular composition was reflected by deconvolution of cell abundances 371 in our Visium data sets, wherein we observed a predominance of Treg, CD8⁺ T cells, 372 macrophages and DCs. Further studies are required to determine whether other members of 373 this core signature contribute to shaping the immunoregulatory environment in leishmaniasis.

374

375	In our previous study of SL_CL patients, we identified elevated expression of IDO1 and PD-
376	L1 in pre-treatment biopsies and demonstrated that an early reduction in PD-L1 after
377	treatment onset was predictive of rate of cure ³² . Although providing a mechanistic basis for
378	how ICs might restrict the efficacy of T cell-dependent chemotherapy, this study did not
379	provide insights into the cellular or molecular mechanisms ultimately responsible for driving
380	IC expression. The results presented here now allow us to propose a model for the regulation
381	of ICs in CL, rooted in spatial interaction mapping and validated through multiple orthogonal
382	approaches: 1) CCL18 ⁺ macrophages recruit IL-32 ⁺ CD8 ⁺ T cells and IL-32 ⁺ Tregs into a
383	myeloid cell niche; 2) $IL-32^+CD8^+T$ cells and $IL-32^+T$ regs induce expression of ICs in
384	DCs and macrophages by paracrine signalling through the as-yet-uncharacterised IL-32
385	receptor, 3) IDO1 ⁺ PD-L1 ⁺ myeloid cells respond to T cell derived cytokines (IFN γ , TNF)
386	and secrete additional M2-polarising cytokines such as IL-24 and IL-1 β , and 4) IDO1 and
387	PD-L1 expressed by DCs and macrophages in the niche promote loss of effector T cell
388	function, through tryptophan starvation and PD-1 signalling respectively (see Graphical
389	Abstract).
390	
391	The study has some limitations. Clinical sampling was limited on ethical grounds to two

biopsies, so we have been unable to evaluate expression levels of IDO1 or PD-L1 at disease
resolution. Although not statistically significant, patients with low abundance of IL32⁺FoxP3⁺ Tregs also showed a trend towards faster healing, a result that deserves further

exploration with larger sample sizes. Logistical constraints associated with studying patients
in an endemic country setting impacted our ability to perform phenotypic and / or functional
characterisation of cells isolated from lesion biopsies. Consequently, our cell deconvolution
approaches may not reflect all cell phenotypes present in CL lesions due to the use of non-

399	matched scRNA-seq data sets. As we were unable to isolate lesional mononuclear cells for
400	in vitro analysis, we cannot formally address the question of T cell antigen specificity or
401	extend our analysis of myeloid cells ex vivo. Finally, we have limited our current analysis to
402	exploring cell-extrinsic regulation of IDO1 and PD-L1 expression by myeloid cells. Ongoing
403	studies are exploring how the regulation of ICs on myeloid cells is regulated in a cell-intrinsic
404	manner following intracellular parasitism by Leishmania (Dey et al, in preparation).
405	
406	In summary, using spatially resolved high dimensional analysis of lesion biopsies, we have
407	mapped the molecular and spatial niches associated with IDO1 and PD-L1 expressing
408	myeloid cells in CL lesions and identified IL-32-expressing CD8 ⁺ T cells as prognostic of rate
409	of cure. Given the commonality of niche composition across multiple forms of dermal
410	leishmaniasis, it is tempting to speculate that our observations may also contribute to local
411	immunoregulation and treatment response in multiple forms of dermal leishmaniasis and that
412	similar regulation of the IDO1/ PD-L1 niche may occur during other infectious and non-
413	infectious diseases.
414	
415	
416	Methods
417	Samples: SL2 cohort, BR cohort and IN cohort.
418	Study design
419	Sri Lanka: The study design for the Sri Lankan cohort was initially published as part of the
420	validation cohort details in Dey et al, 2021 ³² . Briefly, individuals who provided written
421	informed consent and exhibited clinically highly suspected CL lesions were enrolled. On day
422	0, punch biopsies were collected and intralesional sodium stibogluconate (SSG) treatment
423	was administered. Biopsies were processed into formalin-fixed and embedded in paraffin

424	(FFPE) format and then shipped to the University of York (UoY) for subsequent
425	immunological studies described here. These enrolled patients were then monitored for up to
426	6 months to assess complete clinical cure, and given weekly intralesional SSG injections. Of
427	these, $24/25$ patients had achieved complete clinical cure by 6 months, and $1/25$ patients at
428	6.5 months. Out of the 25 patients in this cohort, $23/25$ patient sections were included in the
429	neighbourhood image analysis aimed at identifying neighbours of IDO1 and PD-L1 in stained
430	sections; two were excluded due to insufficient material in the blocks. For including samples
431	for 10x Visium analysis, these 23 patients were further screened for the presence of parasites
432	by using an RNA probe against Amastin to detect parasites in 5u thick sections as described
433	previously ³² . 6/23 were <i>Amastin</i> ⁺ and were included for Visium spatial analysis (P1-P6).
434	Furthermore, out of the 6 samples included for Visium analysis, only four samples could be
435	included in the CosMx analysis due to the availability of sufficient material in the blocks for
436	follow up studies.

437

438 *Brazil*: Patient cohort from Brazil involved 20 patients that agreed to participate by signing 439 the informed consent Form. Patients were diagnosed on the basis of positive polymerase 440 chain reaction and/or indirect immunofluorescence and/or ELISA directed to Leishmania. 441 Depending on the size and location of the lesion and the clinical condition of the patients, 442 treatment was done with systemic pentavalent antimonials (Glucantime) for 20 days; or 443 intralesional pentavalent antimonials (Glucantime) with one application per week for 4 444 weeks; or liposomal amphotericin B for 10 days. Biopsy samples of the lesion were collected 445 on day 0 when the diagnosis was established and patients were followed up after treatment 446 for 6 months to assess clinical cure. To understand IDO1 and CD274 microenvironments in 447 healing and non-healing chronic skin L(V)b. lesions, 20 patient samples were screened for 448 double positivity against diagnostic PCR and ELISA (12/20) and were then stratified on the

449	basis of visual treatment score at 3 months; healed if visual score=0 at 3 months and not
450	healed if visual score >0 at 3 months. Of 12 samples, only 2 patients had healing score>0 at 3
451	months and were included in the study. 2 patients with visual score=0 at 3 months with
452	comparable age, lesion size and lesion duration were then selected from the bigger cohort
453	(12) to include a total of 4 samples that were processed through 10x Visium.
454	
455	India: The initial diagnosis was based on clinical features suggestive of PKDL (presence of
456	papules, nodules and/or hypopigmented macular lesions), a prior history of VL, rK-39
457	positivity, and/or if they resided in an area endemic for VL. In general, cases with
458	hypopigmented patches were considered as macular PKDL, whereas cases with an assortment
459	of papules, nodules, plaques, and/or macules were termed as polymorphic PKDL. Based on
460	these criteria, individuals who were willing and provided written informed consent were
461	enrolled for this study. The patients were examined by a clinician, clinical history recorded,
462	and biological samples (blood and punch biopsy) collected. Subsequently, the diagnosis was
463	confirmed by qPCR ⁹¹ . 2 samples with typical histopathology of PKDL lesions and
464	comparable RNA quality were chosen. These two patients were enrolled between November
465	2019 and August 2021. 5u thick sections were cut and processed through 10x Visium.
466	Lesion characteristics and diagnostic methods. For patients recruited in Sri Lanka and
467	included in the study, lesions were dry nodular ulcerative (n=8), dry ulcers (n=6), dry
468	ulcerated plaques (n=5), wet ulcers (n=2), papular satellite lesions (n=2), nodule with satellite
469	lesions (n=1), ulcerated plaque with satellite lesions (n=1) with mean ulcerated area of 51.13
470	mm2 (\pm SD, 81.1) and mean area of inducation of 1430.2 (\pm SD, 1966.9). In addition to
471	clinical assessment, CL was diagnosed by slit skin smears (SSS) (18/23) and PCR (23/23).
472	Amongst Indian patients, the polymorphic case presented with lesions (papules and nodules)
473	on the face, specifically on the forehead, nose and chin while the macular patient had a hypo

474	pigmented patch on the back. In case of polymorphic cases, the biopsy was collected from a
475	nodule, whereas in macular PKDL, it was from an area of hypopigmentation. In addition to
476	clinical examination by a dermatologist, PKDL was also confirmed by qPCR. Both patients
477	gave a previous history of VL, for which they had received sodium antimony gluconate
478	For patients recruited in Brazil and included in the study, lesions were showed wet ulcers in
479	the lower (3/4) or upper limbs (1/4) with mean ulcerated area of 2475mm2 (\pm SD, 2148). The
480	diagnosis was confirmed by PCR specific for Viannia subgenus (4/4), indirect
481	immunofluorescence (2/4) and ELISA (4/4).
482	
483	Slit skin smears (SSS): For Sri Lankan cohort only, tissue scrapings from a 3mm superficial
484	nick from the active edge of the lesions were used to prepare smears on slides, stained with
485	Giemsa and examined under oil immersion microscopy for the presence of amastigotes.
486	Parasite density was graded from 0 to 6+ according to WHO guidelines for VL ⁹² : 0—no
487	parasites per 1000 high power fields (HPF: x 1000 magnification); 1+: 1-10 parasites per
488	1000 HPFs; 2+: 1–10 parasites per 100 HPFs; 3+: 1–10 parasites per 10 HPFs; 4+: 1–10
489	parasites per HPF; 5+: 10–100 parasites per HPF; and 6+: > 100 parasites per HPF.
490	Amastigote density for each Sri Lankan sample is outlined in Supplementary Table 1.
491	
492	Punch Biopsy: A 3mm diameter full thickness punch biopsy was taken from the edge or
493	centre of the lesion under local anaesthesia, transported in formol saline and then fixed in
494	paraffin blocks and used for H&E or FISH + IF and transcriptome analysis studies.
495	Simultaneously an 2mm diameter punch biopsy was taken for PCR.
496	
497	PCR: DNA extraction was performed from 2mm excision biopsy and was used as an input
498	material for diagnostic PCR for Leishmania positivity as previously described ³² . In Sri

499	Lanka, LITSR/L5.8S specific primers were used that amplifies a 320 bp fragment of ITS1
500	region of Leishmania genus-specific DNA. In Brazil, kDNA specific primers were used that
501	amplify 750 bp kinetoplastid DNA of Leishmania subgenus Viannia 93. In India, DNA
502	extraction was performed using manufacturer's instructions using QIAamp DNA mini kit,
503	Qiagen, Hilden, Germany from a skin biopsy collected in phosphate- buffered saline (20 mM,
504	pH 7.4) and eluted in 50 μ L of DNA elution buffer. Real-time PCR was performed using
505	specific primers for kinetoplast minicircle gene, using 1ul of DNA as input material and 400
506	nM of each primer. DNA isolated from a Leishmania donovani strain MHOM/IN/1983/AG83
507	served as the positive control while negative controls used were DNA from a healthy donor
508	(no amplification), and a reaction mixture with water instead of template DNA (no-template
509	control) ⁹¹ .

Diagnosti	LITSR (forward) 5'-	L 5.8S (reverse) 5'-
c PCR	CTGGATCATTTTCCGATG-3	TGATACCACTTATCGCACTT-3'
primers		
for L. don		
CL		
Diagnosti	B1.	B2.
c PCR	5'-GGGGTTGGTGTAATATAGTG	5'-CTAATTGTGCACGGGGAGG-
primers	G-3'	3'
for <i>L</i> . (<i>V</i>)		
kDNA		
Diagnosti	Forward: 5'-	reverse: 5'-
c PCR	CTTTTCTGGTCCTCCGGGTAGG-	CCACCCGGCCCTATTTTACACC

primers	3'	AA-3'
for <i>L</i> .		
don.		
PKDL		

511

512 ELISA and Indirect immunofluorescence reaction: In Brazil, all sera were tested for 513 immunoglobulin G (IgG) antibodies at 1:50 dilution in the ELISA using whole L. major-like parasite lysate (ELISA-L. major-like) as previously described ⁹⁴. For both antigens, the cut-514 515 off point was determined using a receiver operating characteristic (ROC) curve. The reactivity index (RI) was calculated for each sample by dividing the sample absorbance value 516 by the cut-off. Samples were considered positive if the RI value was \geq 1. The 517 spectrophotometric reading of each well was performed at 450 nm using a Multiskan GO 518 519 instrument (Thermo Scientific, Finland). The IIF test was performed on the slides, containing 520 suspension of fixed promastigotes of Leishmania (Leishmania major-like the promastigotes/MHOM/BR/71/49) as previously described ⁹⁵. Then the slide was observed in 521 522 the fluorescence microscope, with the objective of $250 \times$.

523

524 Sectioning

525 FFPE blocks were placed on cool plate prior to sectioning and 5µm sections were cut and 526 serial sections were placed onto Superfrost glass slides for CosMx or H&E or 10x Visium 527 onto the capture area making sure that all layers of the skin were represented in the cut 528 section.

529

530 Low-resolution spatial transcriptomic mapping of CL lesions using 10x Visium

531	Visium gene expression slides were processed using the Visium Spatial gene expression
532	reagent kits for FFPE as per recommended protocols. In brief, slides were deparaffinised in
533	Xylene twice for 10 minutes each and then stained for hematoxylin and eosin. Stained slides
534	were coverslipped and imaged on an Axioscan slide scanner. Post imaging cover slips were
535	removed, slides were placed in a Visium cassette and were de-crosslinked. Human probes
536	were added overnight after which they were extended and released. Library preparation was
537	done based on manufacturer's instructions and sequenced using a NovaSeq 6000. Raw
538	FASTQ files were aligned to the GRCh38 genome
539	(https://www.ncbi.nlm.nih.gov/datasets/genome/GCF_000001405.40/) and the
540	Spaceranger_1.3.0 (10x) count was used to generate UMI counts per spatial barcode. Raw
541	counts were normalised and analysed further. Code used for analysis and figures is described
542	under "Code Availability".
543	
544	Integration and clustering of 10x Visium data

545 We used Seurat (Seurat_4.3.0) package in R 4.2.3 to analyse spot matrices. Normalisation 546 across spots was performed using SCTransform(). We used FindIntegrationAnchors() 547 function to find anchor spots across samples and then used IntegrateData() to integrate all 548 samples based on 3000 features as identified upon data integration. 30 Principal Components 549 derived using 3000 features in the integrated assay were used as an input for clustering 550 Visium spots with a resolution of 0.5 using FindClusters() and UMAP was used to visualise 551 clustering in two-dimensional space. Differential gene expression (DE)between clusters was 552 calculated first by running PrepSCTFindMarkers() to normalise for median genes as a proxy 553 for sequencing depth. FindAllMarkers() was then used to find DE genes using a minimum 554 setting for log2fold change as 0.25 with genes that were expressed in a minimum of 25% 555 spots (min.pct=0.25). P-value of DE genes was based on a two-tailed Wilcoxon Rank Sum

test. List of DE markers from each cluster was then fed into CellMesh 96 (

- 557 https://uncurl.cs.washington.edu/db_query) using probabilistic model to identify probable cell
- types expressed in cluster spots. Clusters were then annotated based on most abundant cell
- type expressed and then plotted onto each tissue image using SpatialDimPlot function from
- 560 Seurat and required DE genes were visualised using EnhancedVolcano package in R. Spatial
- 561 maps of *IDO1* and *CD274* (PD-L1) were generated using SpatialPlot() function. For
- comparison across My1, My2 and My3, matrices were extracted from Seurat and plotted in
- 563 Graphpad for violin plots.
- 564

565 Deconvolution of Visium spots to identify immune cell abundance

566 We utilized Cell2location 5^{2} to deconvolve cell type composition per 55 μ m Visium spatial

spots. The hyperparameters used were N_cells_per_location=30 and detection_alpha=20,

using the dataset Reynolds *et al* 38 (accession number: E-MTAB-8142;

- 569 www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-8142.) as a skin single-cell reference
- 570 dataset. First, we estimated reference cell type signatures by training a negative binomial

regression model for 1,000 epochs retaining the cell-type annotations from *Reynolds et al.*

- 572 We then used the reference signature model to deconvolute the spatial data using the
- aforementioned hyperparameters, training the Cell2location model for 30,000 epochs. We
- inferred cell abundance per spatial spot using the 5% quantile values of the posterior
- distribution, where the model has high confidence as per the tool's manual. Predicted
- abundances were used to infer compositions in My1, My2, My3, IDO1, CD274 and IDO1/

577 CD274 spots.

578

579 Identifying molecular networks associated with CD274 and IDO1 expression

580	To look for correlation between <i>IDO1</i> and <i>CD274</i> across all spots, all spots covered under the
581	tissue from Sri Lankan patients (n=6) were visualised using FeatureScatter() function in
582	Seurat. Thresholds on the scatterplot were put below or equal to median of total expression of
583	<i>IDO1</i> (1.2) and <i>CD274</i> (0.6). All spots were then annotated as IDO1 spots (<i>IDO1</i> > 1.1 &
584	<i>CD274</i> < 0.5) or CD274 spots (<i>IDO1</i> < 1.1 & <i>CD274</i> > 0.5) or IDO1/ CD274 spots (<i>IDO1</i> >
585	1.1 & $CD274 > 0.5$) or rest of the spots ($IDO1 < 1.1$ & $CD274 < 0.5$). DE genes were then
586	graphed as line plot in GraphPad 9.3.1 whereas the rest were plotted as dot plots using
587	DotPlot function in Seurat in R. A similar strategy was followed for patients from Brazil
588	(n=4) presenting with CL lesions and patients from India (n=2) presenting with PKDL
589	lesions.
590	
591	We performed a pairwise correlation analysis of all genes in the dataset with IDO1 and
592	CD274 using the cor.test() function from the R stats package (version 4.1.1), employing
593	Spearman's ranked correlation method. A significance threshold of 0.05 was applied to
594	identify significant correlations. Subsequently, the top 50 correlated genes from each dataset,
595	which included Visium gene expression data from 6 Sri Lankan CL patients, 4 CL patients
596	from Brazil, and 2 PKDL patients from India, were extracted. These gene sets were then
597	subjected to comparison using Venny 2.0
598	(https://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html) to identify common correlates of
599	IDO1 and CD274 across these three datasets.
600	
601	Single cell resolution spatial transcriptomic mapping of CL lesions using CosMx
602	molecular imager.
603	For CosMx, a single slide containing sections from skin lesions of 4 patients from SL2

604 patients were sent to Nanostring Translational Services lab, Seattle under Technology Access

605	Program (TAP). CosMx Human Universal Cell Characterization RNA Panel (1000-plex) was
606	used to analyse gene expression at subcellular level. Morphology of the tissue was visualised
607	by staining for B2M/CD298, PanCK, OPB (for parasite), CD3 antibodies and DAPI post
608	hybridization of probes. The methods for sample processing and cell segmentation are
609	described in CosMx methods study 53 . A total of 20 Fields of View (FOVs) were created
610	across 4 patient samples. Expression matrix of transcripts along with their x, y and z
611	coordinates, cell ID, metadata, FOV positions were loaded onto Giotto package to create an
612	integrated giotto object in R 56 and then filtered based on minimum expression threshold of
613	1;> 5 features/cell and > 5 cells expressing one feature. Expression matrix was normalised
614	using standard method of data normalisation for total library size followed by scaling for a
615	factor of 6000, log normalisation and z scoring of data by genes and/or cells. Expression
616	values were then regressed for total sum of feature expression and number of features
617	expressed per cell to account for batch to batch variation.

618

619 Clustering and cell type annotation of CosMx data

620 UMAP dimension reduction algorithm was used for individual cell data presentation based on 621 CosMx SMI gene expression profiles. For a further QC, total count numbers and slide ID 622 were projected onto UMAP space to assess data quality and no total count-based clustering 623 bias was found. Coarse cell typing was done using nb_clust, a semi-supervised cell clustering 624 (negative binomial) algorithm developed by NanoString team resulting in detection of 16 625 immune cell types using single cell data sets. 6 unsupervised cell clusters (KC1, KC2, KC3, 626 plasmablast2, fib2 and mac2) were also identified and were labelled on the most enriched cell type based on CellMesh reference database 96 . DE between clusters was done using 627 628 findMarkers_one_vs_all from Giotto package using Gini coefficient Followed by 629 plotMetaDataHeatmap from Giotto package to plot heatmap of gene expression. Cell ID and

630	expression matrix of all cells were then imported into Seurat package and subclustered to
631	identify further subtypes. Myeloid cells (cluster IDs: mac, mac2, mDC, neutrophil, pDC,
632	monocyte, mast) were subclustered into13 subtypes that were annotated on gene expression
633	and projected onto UMAP space. 12% of total cells that showed abundance of border
634	transcripts from nearby cells due to faulty assignment of transcripts were subsetted out.
635	ImageDimplot from Seurat and SpatPlot from Giotto were used to map cell types onto space.
636	
637	Neighbourhood analysis of CD274 and IDO1 expressing cells
638	IDO1 and CD274 values from all myeloid cells were correlated and thresholds were placed
639	that showed clear assignment of all myeloid cells into IDO1mye+ ($IDO1 > 3$ and $CD274 < 3$),

640 CD274mye+ (*IDO1* < 3 and *CD274* >3), $IDO1^+/CD274mye+$ (*IDO1* > 3 and *CD274* >3) and

641 were annotated as such. SpatPlot2D from Giotto package was used to map cell types onto

space. To create a network that revealed spatial relationships and interactions among

643 individual cells, we first used plotStatDelaunayNetwork function from Giotto to estimate

distance between each cell and its neighbours by calculating pairwise distances between cells

and identifying statistically significant connections. We estimated that each cell had 4-6

646 nearest neighbours. We then used createSpatialNetwork from Giotto using k = 4 to limit the

647 number of neighbours to 4.

648

To investigate cellular interactions within the spatial network, we first created an interaction map for IDO1mye⁺, CD274mye⁺, IDO1⁺/ CD274mye⁺ with 4 immediate neighbour cells using annotateSpatialNetwork function from Giotto. To create spatial plots illustrating these interactions, we first used findNetworkNeighbors function to identify these neighbours. Spatial plots were then generated using SpatPlot2D function to visualize the cellular interactions. Cells were color-coded based on their classification as "source" (specified cell;

655	IDO1mye ⁺ or CD274mye ⁺ or IDO1 ⁺ /CD274mye ⁺) or "neighbour" (amongst 4-6 immediate
656	neighbours of specified cell) or "both" (a neighbour and a source cell) or "others" (not a
657	neighbour to specified cell nor a source cell). Cell IDs and cell type annotation of these cells
658	were then imported into UpsetR shiny app ⁵⁷ (<u>https://gehlenborglab.shinyapps.io/upsetr/</u>) to
659	estimate the most abundant neighbour combination to IDO1mye ⁺ or CD274mye ⁺ or
660	IDO1 ⁺ /CD274mye ⁺ cells and into a worksheet to estimate composition of these populations
661	and graphed in GraphPad. For additional validation, neighbour combinations were also
662	checked in an excel sheet to tally neighbour combination numbers. To look at spatial maps of
663	specific interactions, an additional metadata column with information about interacting and
664	non-interacting cell types of the selected cell-cell interaction was created and visualised using
665	spatPlot from Giotto.
666	
667	To look at cytokine and chemokine expression patterns in source and neighbouring cells, cell

IDs of IDO1mye+ or CD274mye+ or IDO1⁺/CD274mye+ source cells and top 5 neighbours

669 (CCL18_mac, Treg, IDO1mye+, CD274mye+, T CD8 memory) were subsetted and violin

670 plots, heatmaps (using Giotto in R) or bar charts (in GraphPad Prism 10) were plotted to look

at cytokine expression in these cells.

672

673 Immunostaining

FFPE sections were obtained from 23 or 25 Sri Lankan patients, with 23 FFPE patient lesion

blocks used for the IDO1, PD-L1, and CD8 staining set due to material constraints. For

FoxP3 staining set, only 22 sections were analysed due to sample detachment during

677 processing. The staining protocol involved following steps: heat fixation at 60°C to ensure

sample adherence, followed by two rounds of 5-minute deparaffinization in histo clear/xylene

at room temperature (RT). Subsequent steps included equilibration in 95% ethanol for 3

680	minutes, 70% ethanol for another 3 minutes, and hydration in distilled water for 3 minutes.
681	Antigen retrieval was achieved through a 15-minute high-pressure treatment with citrate
682	buffer (pH 6.0), followed by a 25-minute standing period at RT. After two 5-minute washes
683	with wash buffer (PBS + 0.5% BSA w/v), tissue sections were delineated with a wax pen.
684	The procedure continued with blocking (PBS + 0.1% Triton X-100 v/v + 5% Normal donkey
685	serum v/v + 5% Normal goat serum v/v + 1% BSA w/v) for 30 minutes, overnight primary
686	antibody incubation with IDO1 (1:200) and PD-L1 (1:500) at 4°C in the fridge, and three 5-
687	minute washes the next day. Secondary antibody staining for 30-45 minutes at RT employed
688	CF750 Donkey Anti-Rabbit IgG CF [™] 750 and Goat anti-Mouse Dy650 at a 1:500
689	concentration. Sections were then incubated with CD8-AF594 for 2h at room temperature.
690	After three more buffer washes, YOYO-1 at 0.2uM concentration was added for 30 minutes
691	in wash buffer. Three final wash buffer washes were performed before applying Prolong
692	Gold mounting media and coverslips.
693	
694	For the IL-32 CD8 set and IL-32 FoxP3, the same protocol was followed with minor
695	adjustments. Antigen retrieval utilized TE buffer (10mM Tris Base, 1mM EDTA, 0.05%
696	Tween 20, pH 9.0), while pre-primary blocking consisted of PBS + 0.1% Triton X-100 v/v +
697	5% Normal goat serum v/v + 1% BSA w/v. The slides were incubated with IL-32 (1:400) and
698	CD8a or FoxP3 overnight at 4°C and were developed with goat anti-rabbit Dylight 650 and
699	Goat anti-mouse AF555 F(ab)2 at a 1:500 concentration, respectively. Notably, no second
700	blocking step was carried out for IL-32 CD8/ FoxP3 set. Detailed antibody information,
701	including catalogue numbers and dilutions, can be found in the reporting summary.
702	

703 Image acquisition and analysis.

704	Whole tissue section mages were acquired using Zeiss AxioScan.Z1 slide scanner at 20x
705	magnification. Identical exposure times and threshold settings were used for each channel on
706	all sections of similar experiments. Whole section images of IDO1, PD-L1, CD8/ FoxP3 and
707	IL-32 was were quantitated using StrataQuest Analysis Software (TissueGnostics, v
708	7.0.1.178). We first segmented nuclei based on YOYO1 staining and then created cell
709	polygons over grey images of CD8 (outside), PD-L1(outside and inside) and IDO1 (outside
710	and inside) using nuclei mask. A cut off was applied on IDO1/PDL-1 mean intensity based
711	on visual inspection of the tissue to delineate IDO1/ PD-L1 $^+/^-$ cells. We then created coded
712	images for each of the markers and used proximity maps function in Strataquest 7.178
713	(https://tissuegnostics.com/products/contextual-image-analysis/strataquest) to generate
714	distance maps at 25, 50 and 100 μ m from IDO1, PD-L1 or IDO1 PD-L1 double positive
715	polygons and then detected CD8 masks within these proximity areas
716	
/	
717	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1
717 718	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 μ m for IL-32 and outside for 1 μ m for CD8 (also a ring
717 718 719	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 μ m for IL-32 and outside for 1 μ m for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was
717 718 719 720	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 μ m for IL-32 and outside for 1 μ m for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask.
717 718 719 720 721	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 µm for IL-32 and outside for 1µm for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask. Cut-offs were also applied to nuclei, IL-32 and CD8/ FoxP3 mean intensity detection to
717 718 719 720 721 722	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 µm for IL-32 and outside for 1µm for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask. Cut-offs were also applied to nuclei, IL-32 and CD8/ FoxP3 mean intensity detection to ensure no false positives were included. The same cut-off was applied for all samples.
 717 718 719 720 721 722 723 	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 µm for IL-32 and outside for 1µm for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask. Cut-offs were also applied to nuclei, IL-32 and CD8/ FoxP3 mean intensity detection to ensure no false positives were included. The same cut-off was applied for all samples. Scattergram was generated with IL-32 and CD8/ FoxP3 mean intensities and gated on
717 718 719 720 721 722 723 724	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 µm for IL-32 and outside for 1µm for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask. Cut-offs were also applied to nuclei, IL-32 and CD8/ FoxP3 mean intensity detection to ensure no false positives were included. The same cut-off was applied for all samples. Scattergram was generated with IL-32 and CD8/ FoxP3 mean intensities and gated on positive IL-32 and CD8/ FoxP3 cells. Upper right quadrant of these scattergrams gave data
717 718 719 720 721 722 723 724 725	For quantification of IL-32 and CD8/ FoxP3, nuclear segmentation was based on YOYO1 and expanded outside of nuclei for 10 µm for IL-32 and outside for 1µm for CD8 (also a ring mask with interior and exterior radius of -0.20 and +0.20 um). As FoxP3 staining was nuclear, cell polygons were created on FoxP3 staining without any expansion on nuclei mask. Cut-offs were also applied to nuclei, IL-32 and CD8/ FoxP3 mean intensity detection to ensure no false positives were included. The same cut-off was applied for all samples. Scattergram was generated with IL-32 and CD8/ FoxP3 mean intensities and gated on positive IL-32 and CD8/ FoxP3 cells. Upper right quadrant of these scattergrams gave data for IL-32 ⁺ CD8 ⁺ / IL-32 ⁺ FoxP3 ⁺ cells.

727 Multivariate Cox proportional hazard model

728	For correlation of IL-32 with cure rates, total IL-32 ^{+,} CD8 ⁺ IL-32 ⁺ and FoxP3 ⁺ IL-32 ⁺ cells
729	per mm2 of tissue section per patient (n=22-25) was computed from image analysis. Patients
730	were then stratified on geomean of total IL-32 (6969.37), CD8 ⁺ IL-32 ⁺ (2800.9), FoxP3 ⁺ IL-
731	32 ⁺ (544.0) expression into IL-32 high (>6969.37; n=14) or low (<6969.37; n=11) and
732	CD8 ⁺ IL-32 ⁺ high (>2800.9; n=13) or low (<2800.9; n=12) and FoxP3 ⁺ IL-32 ⁺ high (>544.0;
733	n=16) or low (<544; n=6). These values were then imported in R and Kaplan Meier survival
734	(cure) curves were generated for IL-32or CD8 ⁺ IL-32 ⁺ or FoxP3 ⁺ IL-32 ⁺ expression groups
735	using the survfit function, and survival differences were assessed with the survdiff function
736	from survminer, survival, ggplot2 packages. We then constructed multivariate hazard models
737	adjusted for participant age and sex, employing the survival and survminer packages. The
738	statistical scores were derived from Wald's statistic value, followed by estimation of hazard
739	ratios, which were visualized on forest plots.

740

741 **RNA isolation and qPCR**

742 The total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) patient samples 743 using RNeasy FFPE Kit (Qiagen) as per manufacturer's protocol. Briefly, 2 x 10µm sections 744 were cut from each block and put into deparaffinization buffer (Qiagen). Sample lysis was 745 done using Proteinase K digestion for 15 minutes. After lysis, samples were incubated at 746 80°C for 15 minutes followed by 15 minutes of DNase treatment. Finally, concentrated RNA 747 was purified using RNeasy MinElute spin columns, and eluted in a volume of 14–30 µl. 748 Purity and concentration of extracted RNAs were checked and quantified by reading at 260 749 and 280 nm in a NanoDrop spectrophotometer (Thermo Fisher). Next, 50ng total RNA was 750 reverse transcribed using Superscript IV first strand cDNA Synthesis Kit (Invitrogen) and 751 random hexamers (Invitrogen) according to manufacturer's protocol.

752	qRT-PCR was performed with Fast SYBR Green Master Mix (ThermoFisher) and primers
753	using a StepOnePlus Real Time PCR System (ThermoFisher). cDNA extracted from LPS
754	(100 ng/ul for 4 hours) stimulated PMA (100 ng/ul) differentiated THP-1 cells line was used
755	as a positive control to optimise primers ⁹⁷ . All primers were optimised by serially diluting
756	LPS stimulated THP-1 cDNA. Relative transcript levels were determined using the $\Delta\Delta$ Ct
757	method using GAPDH/ ACTB as a housekeeping gene and healthy skin. All reactions were
758	performed in duplicates. Primer list used in the study is given in the table below.

759

760

IL32alpha	Forward 5'-GCTGGAGGACGACTTCAAAGA-3'
IL32alpha	Reverse 5'-GGGCTCCGTAGGACTTGTCA-3'
IL32beta	Forward 5'-GAAGACTGCGTGCAGAAGGT-3'
IL32beta	Reverse 5'-CTTTCTATGGCCTGGTGCAT-3'
IL32gamma	Forward 5'-AGGCCCGAATGGTAATGCT-3'
IL32gamma	Reverse 5'-CCACAGTGTCCTCAGTGTCACA-3'
IL32delta	Forward 5'-TCTGTCTCTCTCGGGTCCTCTCT-3'
IL32delta	Reverse 5'-TGTCTCCAGGTAGCCCTCTTTG-3'

761

762

763 Acknowledgements

The authors thank all patients and their families who took part in this study. We also thank all

765 members of the Kaye laboratory at Hull York Medical School, University of York for their

766	useful comments and suggestions on this project, Robert Nica and Simina Laslau at the
767	technical department at Tissue Gnostics for help with Strataquest, TAP team at Nanostring,
768	Seattle specially Emily Killingbeck, Youngmi Kim and Claire Williams for initial support
769	with CosMx and the Biosciences Technology Facility at University of York for support
770	throughout the project. Biorender.com was used to generate the graphical abstract.
771	
772	Author contributions
773	N.S.D., S.D. and P.M.K. conceived the study; N.S.D. and S.D. did the analysis; N.S.D., S.D.,
774	and N.B. conducted experiments; N.S.D and P.M.K wrote the manuscript; P.M.K, S.R.,
775	M.C., and H.G. secured funding; all other co-authors provided materials or clinical
776	assessments for the study and reviewed the manuscript.

778 Data availability

- The sequencing data reported in this paper have been deposited in the GEO database under
- the accession code GEO: TBC. The processed sequencing data is available as Rds files on
- 781 Zenodo: <u>https://doi.org/10.5281/zenodo.10402126</u>. Additional data (**Supplementary Table**
- **4**) related to the figures is also available on figshare (DOI:
- 783 <u>https://doi.org/10.6084/m9.figshare.24803511</u>).
- 784

785 **Code availability**

- 786 Code used for analysis (including that for generating Figs from Visium seq data and CosMx
- 787 imaging data) in this study is available at https://github.com/NidhiSDey/leish-ME
- 788

789 Ethics statements

790 Institutional review board statement

791	Written informed consent including for lesion photographs was obtained from participants
792	under a protocol for the project titled "Towards a global research network for the molecular
793	pathological stratification of leishmaniasis" approved by Ethical Review Committee of the
794	Faculty of Medical Sciences, University of Jayewardenepura (ref: 780/13 & 52/17), Ethics
795	Committee of the Faculdade de Medicina, Universidade de Sao Paulo- CAAE
796	39964520.8.0000.0068, Institutional Ethics Committee of School of Tropical Medicine,
797	Kolkata and Institute of Post Graduate Medical Education and Research, Kolkata
798	(IPGME&R/IEC/2019/208) and the Biology Ethics Committee (ref: PK201805), Department
799	of Biology, University of York. This study was conducted according to the Declaration of
800	Helsinki (2013).

801

802 Inclusion and Ethics statement

- 803 We affirm that our research upholds the highest ethical standards and contributes to the
- advancement of immunological science in an inclusive and responsible manner.

805

806 **Funding**

- 807 This work was supported by funding from the UK Medical Research Council / UK Aid
- Global Challenges Research Fund (MR/P024661/1 to PMK, SR, HG, and MC), a Wellcome
- 809 Trust Senior Investigator Award (WT104726 and WT224290 to PMK) and Fundac□ão de
- Amparo à Pesquisa do Estado de São Paulo (2018/14398-0) and fellowship (2019/25393-1)

811 to HG.

812

813 **Competing interests**

814 All authors declare no competing interests.

815 Figures and Extended Figures

Fig.1: 10x Visium guided spatial transcriptomics reveals organised domains in CL lesions from Sri Lanka



816

817 Fig. 1: Spatial transcriptomics identifies spatial domains in *L. donovani* CL lesions.

818 a, Patient P3 showing lesion macroscopic features. b, Left, histology of P3 shows dense 819 dermal infiltrate (Hematoxylin and eosin; H&E; Bar 500µm). Right, Higher magnification of 820 site of parasitism; top, H&E and bottom, anti-Leishmania OPB staining. Bar 10 µm. Parasites 821 indicated in H&E by yellow arrow. c, UMAP projection of Visium spots from patients P1-P6 822 coloured by patient ID. d, as (c) but clustered, coloured and labelled by gene expression. e, Heatmap showing the top 10 genes enriched in each cluster. **f**, Spatial map for patient P3 823 824 coloured by clusters identified in (d). g-h, Spatial feature plots for P3 showing normalised 825 values of CD274 (g) and IDO1 (h) i, IDO1 and CD274 violin plots for My1-3 clusters for P1-826 6(red dotted line, mean; black dotted lines, IC range) p-values for group mean ranks 827 compared by Kruskal-Wallis one-way test.



Extended Data Fig. 1: Patient photographs, histological staining of sections and spatial maps of spot clusters from

829

Extended Data Fig 1: Spatial transcriptomics identifies spatial domains in *Leishmania donovani* infected CL skin.

a, Photographs of patients P1, P2, P4, P5 and P6. b, H&E images of patients described in (a)
showing dense cellular infiltrate. c, Violin plot showing overall gene counts across all
patients. Red line shows median gene count across all samples (n=6) d, Spatial maps for
patients described in (a) coloured by clusters identified in Fig.1f. e-k, Spatial feature plot for
P3 overlaid on H&E showing normalised gene expression of top genes expressed in each
cluster: *KRT14*, *CCL18*, *JCHAIN*, *COL1A1*, *CCL19*, *CHIT1* and *SPARCL1* (left panels)
and spatial maps of respective clusters (right panels).



Extended Data Fig. 2 :Decomposition of cell types in 10x Visium spots

840

841 Extended Data Fig. 2: Deconvolution of cell types in 10x Visium spots

a, Bar plot showing 5th quantile predicted cell abundances per spot for P1-P6. Black line

represents median value, bar indicates interquartile range. **b**, Donut representation of

predicted average abundance for the 10 most abundant cell types in My1-3 spots. Total

(inside each donut) depicts average number of cells predicted across My1-3 spots. c-l,

Predicted abundance of cell types in lesion core and T-rich regions (shown for patient P3).



Fig. 2: Single cell imaging of cutaneous lesions from Sri Lanka

848 849

850 Fig. 2: Single-cell transcriptomic imaging of cutaneous lesions from Sri Lanka

a,b, Single cell spatial mapping of CL lesions. a, UMAP representation of single cell data
from 4 patients coloured by cell type b, single cell representation of P3 lesion biopsy
generated by stitching individual FOVs. Boxes 1-4 provide higher magnification views of
selected regions of interest. c. Same as (a) but for sub-clustered myeloid cells only. d, Dot
plot showing gene expression across the sub-clustered myeloid cell types in (c). e,
localisation of DC3, moDC2 and on patient P3 with representative magnified regions of

857 interest.



Extended Data Fig. 3: FOV positions, patient annotations, gene expression and cell number per cluster

Extended Data Fig. 3: FOV positions, patient annotations, gene expression and cell number per cluster

a, H&E images for patients P3-P6 showing FOV analysed using Nanostring CosMx. Bar 500 μ m **b**, Bar plots showing total cell numbers probed per patient. **c**, Cells were visualised in UMAP space and coloured by patient identity. **d**-**e**, Bar plots showing number of genes (**d**) and negative probes (**e**) detected per cell in the same dataset. **f**, Heat map showing top genes expressed by the identified cell types in all 4 patients. **g**, Stacked bar plot showing total cell counts across all patients for each population.

867



Extended Data Fig. 4: Spatial maps of cell types onto P3 section

868 869 Extended Data Fig. 4: Spatial maps of cell types onto P3 section

a-h, Single-cell spatial mapping of indicated cell types for patient P3. i-j, Violin plots
showing *IDO1* (a) and *CD274* (b) expression across DC3, moDC2, cDC2, infl_mac1 and
DC1 cell types (n=4 patients). Average expression of *IDO1* and *CD274* was computed across
all clusters and cell types that showed upper quartile expression were plotted.



Fig. 3: 10x Genomics Visium: 50 µm neighbourhoods of IDO1+ and CD274+ cells

875

Fig. 3: 55 μm neighbourhoods of *IDO1*⁺ and *CD274*⁺ cells

877 a, Scatterplot of *IDO1* and *CD274* normalised gene expression for all 55um Visium spots (for patients P3-P6). Thresholds were drawn at x=1.1 and y = 0.5 to classify spots as IDO1, 878 879 CD274, IDO1/ CD274 or rest of the spots. b. Representative spatial plot coloured by spot 880 class in (a) shown for P3. Insets identify lesion core and dermal T cell rich regions as inferred from Visium and CosMx datasets. c, Cytokine, chemokine, or receptor abundance by IDO1 881 882 and PD-L1 expression class described in (a) across n=4 patients. d-k, Spatial feature plots for 883 cytokines, chemokines, and interleukins from (c) in lesion core and T cell rich area for patient 884 P3.



888 Extended Data Fig. 5: Characterisation of *IDO1*, *CD274* and *IDO1/ CD274* rich spots

a, Spatial feature plots for cytokines, chemokines and interleukins for patients P1, P2, P4-P6.
b-d, Bar plot showing 5th quantile top 20 predicted cell abundances for IDO and PD-L1
classes defined in (a) across all patient lesions (P1-P6). Black line represents median value,
bar indicates interquartile range. e, Differential gene expression for selected genes across the
grouping from (a). Log2Fold change cut off was set at 0.3 and p value >0.01. Data shown is
from all 6 patients. f-g, Spatial feature plots for additional selected genes in lesion core and T
cell rich area for patient P3.





897 Fig. 4: Phenotype of IDO1/ CD274+ myeloid cells and neighbours

896

898 a, Scatter plot of CD274 and IDO1 expression on myeloid cells in CosMx dataset. Thresholds 899 at y=3 and x=3 were used to classify cells as single of double positive for IDO1 and CD274 900 (n=4 patients; P3-P6). **b**, Spatial plot for P3 coloured by class defined in (a). **c**, Pie chart of 901 IDO1/ CD274mye⁺ cells by myeloid cell subset **d**, Cartoon representation of neighbourhood 902 analysis (see M&M for details). e, Spatial map of IDO1^{+/} CD274mye⁺ as "source" or "both" 903 shown with neighbours. **f**, UpsetR bar plot of cell types classed as neighbours of $IDO1^+/$ 904 CD274mye+ cells. Top 15 neighbour combinations are shown from 2418 source neighbour 905 pairs. Connecting lines under the bar plot show neighbour combinations. Vertical bars 906 represent total numbers of each combination while the horizontal plots indicate the total 907 count of cell types as neighbours irrespective of the combination. g-i, Representative FOV 908 showing spatial plots of IDO1⁺/ CD274mye⁺ cells (pink) interacting with CD8 mem (red 909 dots, \mathbf{g}), Treg (magenta, \mathbf{h}) and CCL18_mac (blue in \mathbf{i}). Other cells not in neighbour 910 combinations are depicted with an "oth_" prefix below figure j, Immunohistochemistry 911 showing expression of IDO1, PD-L1 and CD8A protein expression. k. Quantitative image 912 analysis of (i) from n=23 patients. Left panel shows imaging masks in shades of grey at 25, 913 50 and 100 μ m diameter from IDO1⁺ PD-L1⁺ cells. Right panel shows proportions of CD8⁺ 914 cells by distance from $IDO1^+ PD-L1^+$ double positive cell. Friedman's one-way test with

- 915 Dunn's adjustment for multiple comparisons. Adjusted p-values are given. l-q, Box and
- 916 whisker plots showing minimum and maximum expression of *IL32* (**I**), *CXCL9* (**m**), *CCL18*
- 917 (n), *IL24* (o), *IFNGR2* (p) and *IL1B* (q) in top 5 neighbours from (f). One-way Kruskal
- 918 Wallis test. Mean (+) and median (vertical line) are indicated inside bars. Dunn's test
- 919 corrected for multiple comparisons. Adjusted p -values are given.



Extended Data Fig. 6: Phenotype and neighbours of IDO1⁺, CD274⁺ myeloid cells

921 Extended Data Figure 6: Phenotype and neighbours of IDO1⁺ and CD274⁺ myeloid cells

a-b, Pie chart for IDO1mye⁺ (**a**) and CD274mye⁺ (**b**) cells by myeloid subset (n=4 patients). 922 923 c, Box and whiskers plots showing the cellular distances when a Delauney network is created 924 for up to 22 immediate neighbours. Data for n=4 patients as in (a,b). **d**, Bar plot to show 925 number of cells with between 3-22 immediate neighbours. e, f. Spatial plot of single cells for 926 P3 coloured with "source" or "both" being either IDO1mye⁺ (e) or CD274mye⁺ (f). g-h, 927 UpsetR plots for IDO1mye⁺ (g) or CD274mye⁺ (h) cells. 15 most frequent heterotypic 928 interactions are shown from n = 5370 IDO1mye+ and n = 4,308 CD274mye+neighbour source 929 pairs, respectively. Connecting lines under the bar plot show neighbour combinations. We 930 have also provided all the possible neighbour combinations in the source data file 931 (Supplementary Table 4). Vertical bars represent total numbers of each combination while 932 the horizontal plots indicate the total count of cell types as neighbours irrespective of the 933 combination. i-j, Quantitative image analysis (n=23 patients) depicting proportions of CD8⁺ 934 cells (yellow) present within 25,50, 100 μ m and >100 μ m distance (left panels) from IDO1⁺ 935 (i) and PD-L1⁺ (j) cells. Cyan and red cell masks are drawn over IDO1 and PD-L1 positive 936 cells respectively. Friedman's one-way test with Dunn's adjustment was applied for multiple 937 comparisons. Adjusted p-value are given. k-l, Violin plots showing expression of CCL18, 938 IL24, IL1B, IFNGR2, CXCL9, IL32, TNFSF14 and FASLG in the top 5 neighbours of 939 IDO1mye+ (i), and CD274mye+(j) cells (n=4 patients). m, Heat map showing phenotype of 940 T CD8 memory and Treg cells. Scale shows gini coefficient z scores (n=4 patients).





942

943

944 Extended Data Fig. 7: Isoforms of IL32 in CL patients

a, Fold change of *IL32* α , β , γ and δ isoforms with respect to GAPDH and healthy skin in Sri 945

Lankan CL patients (n=2) and L.(V.) braziliensis CL patients. Bars show mean +/- standard 946

deviation. 947





949

950

951 Fig. 5: IDO1 and CD274 niches in different dermal variants of leishmaniasis

952

a, CL lesion caused by L. braziliensis in patient Lb P1 from Brazil. b, H&E images of a 5µm 953 954 section from (a) showing dense cell infiltration in the dermis. C, Polymorphic PKDL lesion 955 caused by L. donovani in patient PKDL P1 from India. d, H&E image of (c). e-f, Spatial plots showing the gene expression for *IDO1* and *CD274* on Lb_P1 (e) and PKDL_P1 (f). g, 956 957 Scatter plot showing CD274 and IDO1 expression in all spots from L. b infected CL skin 958 lesions (n=4). Thresholds at y=0.2 and x=0.5 used to classify spots. **h**, Spatial plot for L.b 959 patients coloured by class as in (g). i, Spatial plot of IDO1 and PD-L1 classes for PKDL 960 patients (n=2) derived from Extended Data Fig. 8h. j-k, Venn diagrams indicating overlap 961 amongst top 50 genes per disease correlating with *IDO1* (j) and *CD274* (k).



Extended Data Fig. 8: IDO1 and CD274 microenvironments in L.b CL and L.don PKDL lesions

962

Extended Data Fig. 8: *IDO1*+ and *CD274*+ microenvironments in *L. braziliensis* and *L. donovani* infected CL and PKDL lesions respectively.

a, CL lesions caused by L. braziliensis. Images for patients L.b_P2-P4. b, Matched H&E 965 966 images of 5μ m sections of lesions in (a). Mild inflammatory infiltrate and extensive fibrosis was seen in L.b. P2. c-d, Macular PKDL lesion caused by L. donovani. Image for patient 967 968 PKDL_P2 (c) and corresponding histology shown in an H&E image (d). e-f, Spatial plots showing gene expression for IDO1 (e) and CD274 (f) for patients L. b. P2-P4. P2 showed 969 very limited expression of *IDO1* and *CD274* with no overlap between the two expression 970 patterns. g, Spatial plots showing the gene expression of *IDO1* (c) and *CD274* (d) for macular 971 972 L. don PKDL_P2. h, Scatter plot showing CD274 and IDO1 expression across all spots from 973 L. don PKDL_P1 and P2, with thresholds at y=0.2 and x=0.2. i-j, Spatial plots coloured by 974 class for $L.b_P2-4$ (i) and PKDL_P2 (j). 975



Extended Data Fig. 9: Phenotyping IDO1 and CD274 microenvironments in L.b CL and L.don PKDL lesions

977

978

979 Extended Data Fig. 9: Phenotyping *IDO1*⁺ and *CD274*⁺ microenvironments in *L*. 980 *braziliensis* CL and *L. donovani* PKDL and lesions.

a, Dot plot showing differentially expressed cytokines, chemokines, interleukins, TNF and
interferon related and immune checkpoint markers between IDO1 and CD274 classes in *L.b.*CL patients (n=4; a) and PKDL patients (n=2, b). Cut off was p<0.05, Log2Fold = 0.25. c-f,
Spatial plots showing gene expression for *CXCL9* and *IL32* in *L.b_*P1 and PKDL_ P1. g-j,
Genes correlating with *IDO1* (g,i), and *CD274* (h, j) from all *L. b.* CL patients (g,h) and
PKDL patients (i-j). Pearson's correlation coefficients are plotted in decreasing order
(p<0.05).



Fig. 6: Lesional IL-32 expression is prognostic of cure rate in Sri Lanka

989

990

Fig. 6 Lesion IL-32⁺ T cells are prognostic for rate of cure following treatment for CL in Sri Lanka

a, IL-32 protein expression in Sri Lankan CL. b, Stratification of 25 patients based on 993 994 geomean density of dermal IL- 32^+ cells (low, n=11, High , n=14). Horizontal bars indicate median value. **** p-value <0.0001 (Two-tailed Mann Whitney test). c, Kaplan Meier plot 995 showing treatment response rate for IL-32 Low and High groups. Shaded area indicates 95% 996 997 CI. p- value for Log rank (Mantel-Cox) test is shown. d, Forest plot of Cox proportional hazard model for IL-32⁺ low vs. IL-32⁺ high (reference), adjusted for age and sex. Hazard 998 999 ratio (HR; 95% CI) and p value for each covariate is shown. e-h. same as (a-d) for IL-32⁺ 1000 FoxP3⁺ cells (n=22 patients) i-l, same as (a-d) for IL-32⁺CD8 α ⁺ cells (n=25 patients). Scale bar in (a), (e), and (i) is 100 µm. 1001

1002 **References**

- 10031.Scott, P. & Novais, F.O. Cutaneous leishmaniasis: immune responses in protection and1004pathogenesis. Nat Rev Immunol 16, 581-592 (2016).
- 1005 2. Heyde, S. *et al.* CD11c-expressing Ly6C+CCR2+ monocytes constitute a reservoir for efficient 1006 Leishmania proliferation and cell-to-cell transmission. *PLoS Pathog* **14**, e1007374 (2018).
- Costa-da-Silva, A.C. *et al.* Immune Responses in Leishmaniasis: An Overview. *Trop Med Infect Dis* 7 (2022).
- Samant, M., Sahu, U., Pandey, S.C. & Khare, P. Role of Cytokines in Experimental and Human
 Visceral Leishmaniasis. *Front Cell Infect Microbiol* **11**, 624009 (2021).
- 10115.Bogdan, C. Macrophages as host, effector and immunoregulatory cells in leishmaniasis:1012Impact of tissue micro-environment and metabolism. *Cytokine X* 2, 100041 (2020).
- 10136.Novais, F.O. & Scott, P. CD8+ T cells in cutaneous leishmaniasis: the good, the bad, and the1014ugly. Semin Immunopathol **37**, 251-259 (2015).
- 1015 7. Lecoeur, H., Prina, E., Gutierrez-Sanchez, M. & Spath, G.F. Going ballistic: Leishmania nuclear
 1016 subversion of host cell plasticity. *Trends Parasitol* 38, 205-216 (2022).
- 10178.Sacks, D. & Noben-Trauth, N. The immunology of susceptibility and resistance to Leishmania1018major in mice. Nat Rev Immunol 2, 845-858 (2002).
- Tomiotto-Pellissier, F. *et al.* Macrophage Polarization in Leishmaniasis: Broadening Horizons.
 Front Immunol 9, 2529 (2018).
- 102110.Ajdary, S., Alimohammadian, M.H., Eslami, M.B., Kemp, K. & Kharazmi, A. Comparison of the1022immune profile of nonhealing cutaneous Leishmaniasis patients with those with active1023lesions and those who have recovered from infection. Infect Immun 68, 1760-1764 (2000).
- 102411.Manamperi, N.H. et al. In situ immunopathological changes in cutaneous leishmaniasis due1025to Leishmania donovani. Parasite Immunol **39** (2017).
- 102612.Montes de Oca, M. et al. Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-1027Mediated Tissue Pathology. PLoS Pathog 12, e1005398 (2016).
- 1028 13. Katara, G.K., Ansari, N.A., Verma, S., Ramesh, V. & Salotra, P. Foxp3 and IL-10 expression
 1029 correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis
 1030 (PKDL) patients. *PLoS Negl Trop Dis* 5, e1171 (2011).
- 1031 14. Bourreau, E., Prevot, G., Gardon, J., Pradinaud, R. & Launois, P. High intralesional interleukin 1032 10 messenger RNA expression in localized cutaneous leishmaniasis is associated with
 1033 unresponsiveness to treatment. *J Infect Dis* 184, 1628-1630 (2001).
- 103415.Amorim, C.F. *et al.* Variable gene expression and parasite load predict treatment outcome in1035cutaneous leishmaniasis. Sci Transl Med 11 (2019).
- 103616.de Freitas, E.S.R. & von Stebut, E. Unraveling the Role of Immune Checkpoints in1037Leishmaniasis. Front Immunol 12, 620144 (2021).
- 1038 17. Wykes, M.N. & Lewin, S.R. Immune checkpoint blockade in infectious diseases. *Nat Rev*1039 *Immunol* 18, 91-104 (2018).
- 104018.Paluch, C., Santos, A.M., Anzilotti, C., Cornall, R.J. & Davis, S.J. Immune Checkpoints as1041Therapeutic Targets in Autoimmunity. Front Immunol **9**, 2306 (2018).

1042 1043	19.	He, X. & Xu, C. Immune checkpoint signaling and cancer immunotherapy. <i>Cell Res</i> 30 , 660- 669 (2020).
1044 1045	20.	Carlin, J.M., Borden, E.C., Sondel, P.M. & Byrne, G.I. Interferon-induced indoleamine 2,3- dioxygenase activity in human mononuclear phagocytes. <i>J Leukoc Biol</i> 45 , 29-34 (1989).
1046 1047	21.	Popov, A. & Schultze, J.L. IDO-expressing regulatory dendritic cells in cancer and chronic infection. <i>J Mol Med (Berl)</i> 86 , 145-160 (2008).
1048 1049	22.	Merlo, L.M.F., Peng, W. & Mandik-Nayak, L. Impact of IDO1 and IDO2 on the B Cell Immune Response. <i>Front Immunol</i> 13 , 886225 (2022).
1050 1051	23.	Munn, D.H. <i>et al.</i> Inhibition of T cell proliferation by macrophage tryptophan catabolism. <i>J</i> <i>Exp Med</i> 189 , 1363-1372 (1999).
1052 1053	24.	Munn, D.H. <i>et al.</i> Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. <i>J Clin Invest</i> 114 , 280-290 (2004).
1054 1055 1056	25.	Fallarino, F. <i>et al.</i> The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. <i>J Immunol</i> 176 , 6752-6761 (2006).
1057 1058	26.	Huang, X., Zhang, F., Wang, X. & Liu, K. The Role of Indoleamine 2, 3-Dioxygenase 1 in Regulating Tumor Microenvironment. <i>Cancers (Basel)</i> 14 (2022).
1059 1060	27.	Makala, L.H. <i>et al.</i> Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression. <i>J Infect Dis</i> 203 , 715-725 (2011).
1061 1062	28.	Lu, D. <i>et al.</i> Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. <i>J Immunol Res</i> 2019 , 1919082 (2019).
1063 1064 1065	29.	Ludovini, V. <i>et al</i> . High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. <i>Genes (Basel)</i> 12 (2021).
1066 1067	30.	Della Corte, C.M. <i>et al.</i> Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC. <i>J Transl Med</i> 20 , 541 (2022).
1068 1069	31.	Kjeldsen, J.W. <i>et al.</i> A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. <i>Nat Med</i> 27 , 2212-2223 (2021).
1070 1071	32.	Dey, N.S. <i>et al.</i> Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis. <i>J Clin Invest</i> 131 (2021).
1072 1073	33.	Keren, L. <i>et al.</i> A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging. <i>Cell</i> 174 , 1373-1387 e1319 (2018).
1074 1075	34.	Schalper, K.A. <i>et al.</i> Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <i>Clin Cancer Res</i> 23 , 370-378 (2017).
1076 1077	35.	McCaffrey, E.F. <i>et al.</i> The immunoregulatory landscape of human tuberculosis granulomas. <i>Nat Immunol</i> 23 , 318-329 (2022).
1078 1079	36.	Lima, H.R. <i>et al.</i> Immune Checkpoints in Leprosy: Immunotherapy As a Feasible Approach to Control Disease Progression. <i>Front Immunol</i> 8 , 1724 (2017).
1080 1081 1082	37.	Gulati, N., Suarez-Farinas, M., Correa da Rosa, J. & Krueger, J.G. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. <i>F1000Res</i> 4 , 149 (2015).

1083 1084	38.	Reynolds, G. <i>et al.</i> Developmental cell programs are co-opted in inflammatory skin disease. <i>Science</i> 371 (2021).
1085 1086	39.	Pallotta, M.T. <i>et al.</i> Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. <i>FEBS J</i> 289 , 6099-6118 (2022).
1087 1088	40.	Liu, M. <i>et al.</i> Targeting the IDO1 pathway in cancer: from bench to bedside. <i>J Hematol Oncol</i> 11 , 100 (2018).
1089 1090 1091	41.	Shklovskaya, E. & Rizos, H. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. <i>Int J Mol Sci</i> 21 (2020).
1092 1093	42.	Chen, S. <i>et al</i> . Mechanisms regulating PD-L1 expression on tumor and immune cells. <i>J</i> <i>Immunother Cancer</i> 7 , 305 (2019).
1094 1095	43.	da Fonseca-Martins, A.M. <i>et al.</i> Leishmania Parasites Drive PD-L1 Expression in Mice and Human Neutrophils With Suppressor Capacity. <i>Front Immunol</i> 12 , 598943 (2021).
1096 1097	44.	Donovan, M.J. <i>et al.</i> Indoleamine 2,3-dioxygenase (IDO) induced by Leishmania infection of human dendritic cells. <i>Parasite Immunol</i> 34 , 464-472 (2012).
1098 1099	45.	Hofmeyer, K.A., Jeon, H. & Zang, X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection- induced cytotoxic T lymphocyte exhaustion. <i>J Biomed Biotechnol</i> 2011 , 451694 (2011).
1100 1101 1102	46.	Barth, H. & Raghuraman, S. Persistent infectious diseases say - IDO. Role of indoleamine-2,3- dioxygenase in disease pathogenesis and implications for therapy. <i>Crit Rev Microbiol</i> 40 , 360-368 (2014).
1103 1104	47.	Xia, C., Braunstein, Z., Toomey, A.C., Zhong, J. & Rao, X. S100 Proteins As an Important Regulator of Macrophage Inflammation. <i>Front Immunol</i> 8 , 1908 (2017).
1105 1106	48.	Chenivesse, C. <i>et al</i> . Pulmonary CCL18 recruits human regulatory T cells. <i>J Immunol</i> 189 , 128- 137 (2012).
1107 1108	49.	Barkal, A.A. <i>et al.</i> CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. <i>Nature</i> 572 , 392-396 (2019).
1109 1110	50.	Vogt, L. <i>et al.</i> VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. <i>J</i> <i>Clin Invest</i> 116 , 2817-2826 (2006).
1111 1112	51.	Coletta, S. <i>et al.</i> The immune receptor CD300e negatively regulates T cell activation by impairing the STAT1-dependent antigen presentation. <i>Sci Rep</i> 10 , 16501 (2020).
1113 1114	52.	Kleshchevnikov, V. <i>et al.</i> Cell2location maps fine-grained cell types in spatial transcriptomics. <i>Nat Biotechnol</i> 40 , 661-671 (2022).
1115 1116	53.	He, S. <i>et al</i> . High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. <i>Nat Biotechnol</i> 40 , 1794-1806 (2022).
1117 1118 1119	54.	Cambier, S., Gouwy, M. & Proost, P. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention. <i>Cell Mol Immunol</i> 20 , 217-251 (2023).
1120 1121 1122	55.	Frederick, M.J. <i>et al</i> . In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. <i>Am J Pathol</i> 156 , 1937-1950 (2000).

1123 1124	56.	Dries, R. <i>et al.</i> Giotto: a toolbox for integrative analysis and visualization of spatial expression data. <i>Genome Biol</i> 22 , 78 (2021).
1125 1126	57.	Lex, A., Gehlenborg, N., Strobelt, H., Vuillemot, R. & Pfister, H. UpSet: Visualization of Intersecting Sets. <i>IEEE Trans Vis Comput Graph</i> 20 , 1983-1992 (2014).
1127 1128	58.	Liu, Y. <i>et al</i> . Myeloma-derived IL-32gamma induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis. <i>Oncoimmunology</i> 11 , 2057837 (2022).
1129 1130 1131	59.	Ohmatsu, H. <i>et al.</i> IL-32 induces indoleamine 2,3-dioxygenase(+)CD1c(+) dendritic cells and indoleamine 2,3-dioxygenase(+)CD163(+) macrophages: Relevance to mycosis fungoides progression. <i>Oncoimmunology</i> 6 , e1181237 (2017).
1132 1133 1134	60.	Yan, H. <i>et al.</i> Multiple myeloma cell-derived IL-32gamma increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression. <i>Cancer Lett</i> 446 , 38-48 (2019).
1135 1136 1137	61.	Galdino, H., Jr. <i>et al.</i> Interleukin 32gamma (IL-32gamma) is highly expressed in cutaneous and mucosal lesions of American Tegumentary Leishmaniasis patients: association with tumor necrosis factor (TNF) and IL-10. <i>BMC Infect Dis</i> 14 , 249 (2014).
1138 1139	62.	Farias Amorim, C. <i>et al.</i> Localized skin inflammation during cutaneous leishmaniasis drives a chronic, systemic IFN-gamma signature. <i>PLoS Negl Trop Dis</i> 15 , e0009321 (2021).
1140 1141 1142	63.	Kong, F. <i>et al.</i> Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease Promoting Phenotype. <i>PLoS Pathog</i> 13 , e1006165 (2017).
1143 1144 1145	64.	Rodrigues, V. <i>et al</i> . Transcriptional Analysis of Human Skin Lesions Identifies Tryptophan-2,3- Deoxygenase as a Restriction Factor for Cutaneous Leishmania. <i>Front Cell Infect Microbiol</i> 9 , 338 (2019).
1146 1147	65.	Christensen, S.M. <i>et al.</i> Meta-transcriptome Profiling of the Human-Leishmania braziliensis Cutaneous Lesion. <i>PLoS Negl Trop Dis</i> 10 , e0004992 (2016).
1148 1149 1150	66.	Shekarian, T. <i>et al.</i> Immunotherapy of glioblastoma explants induces interferon-gamma responses and spatial immune cell rearrangements in tumor center, but not periphery. <i>Sci Adv</i> 8 , eabn9440 (2022).
1151 1152	67.	Shin, E.C., Sung, P.S. & Park, S.H. Immune responses and immunopathology in acute and chronic viral hepatitis. <i>Nat Rev Immunol</i> 16 , 509-523 (2016).
1153 1154	68.	Chevalier, M.F. & Weiss, L. The split personality of regulatory T cells in HIV infection. <i>Blood</i> 121 , 29-37 (2013).
1155 1156	69.	Winheim, E. <i>et al.</i> Impaired function and delayed regeneration of dendritic cells in COVID-19. <i>PLoS Pathog</i> 17 , e1009742 (2021).
1157 1158 1159	70.	Pett, S.L. <i>et al</i> . Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. <i>Open Forum Infect Dis</i> 5 , ofx228 (2018).
1160 1161	71.	Tang, Q. <i>et al</i> . The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Front Immunol</i> 13 , 964442 (2022).
1162 1163	72.	Danenberg, E. <i>et al.</i> Breast tumor microenvironment structures are associated with genomic features and clinical outcome. <i>Nat Genet</i> 54 , 660-669 (2022).

1164 1165	73.	Hoch, T. <i>et al.</i> Multiplexed imaging mass cytometry of the chemokine milieus in melanoma characterizes features of the response to immunotherapy. <i>Sci Immunol</i> 7 , eabk1692 (2022).
1166 1167	74.	Honkala, A.T., Tailor, D. & Malhotra, S.V. Guanylate-Binding Protein 1: An Emerging Target in Inflammation and Cancer. <i>Front Immunol</i> 10 , 3139 (2019).
1168 1169 1170	75.	Hu, Z.W. <i>et al.</i> Ferroptosis Driver SOCS1 and Suppressor FTH1 Independently Correlate With M1 and M2 Macrophage Infiltration in Head and Neck Squamous Cell Carcinoma. <i>Front Cell Dev Biol</i> 9 , 727762 (2021).
1171 1172 1173	76.	Moll, H., Flohe, S. & Rollinghoff, M. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. <i>Eur J Immunol</i> 25 , 693-699 (1995).
1174 1175	77.	Lee, S.H. <i>et al</i> . Mannose receptor high, M2 dermal macrophages mediate nonhealing Leishmania major infection in a Th1 immune environment. <i>J Exp Med</i> 215 , 357-375 (2018).
1176 1177 1178	78.	Romano, A. <i>et al.</i> Divergent roles for Ly6C+CCR2+CX3CR1+ inflammatory monocytes during primary or secondary infection of the skin with the intra-phagosomal pathogen Leishmania major. <i>PLoS Pathog</i> 13 , e1006479 (2017).
1179 1180	79.	Tietscher, S. <i>et al.</i> A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. <i>Nat Commun</i> 14 , 98 (2023).
1181 1182	80.	Adema, G.J. <i>et al.</i> A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. <i>Nature</i> 387 , 713-717 (1997).
1183 1184	81.	Cardoso, A.P. <i>et al.</i> The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment. <i>Cytokine Growth Factor Rev</i> 60 , 107-119 (2021).
1185 1186 1187	82.	Rao, L.Z. <i>et al</i> . IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages. <i>Cell Death Differ</i> 28 , 1270-1283 (2021).
1188 1189	83.	Hsieh, S.L. & Lin, W.W. Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions. <i>J Biomed Sci</i> 24 , 39 (2017).
1190 1191 1192	84.	del Rio, M.L. <i>et al</i> . Immunotherapeutic targeting of LIGHT/LTbetaR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells. <i>MAbs</i> 8 , 478-490 (2016).
1193 1194	85.	Yu, K.Y. <i>et al</i> . A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. <i>J Biol Chem</i> 274 , 13733-13736 (1999).
1195 1196	86.	Chang, Y.C. <i>et al</i> . Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. <i>Blood</i> 111 , 5054-5063 (2008).
1197 1198	87.	Aass, K.R., Kastnes, M.H. & Standal, T. Molecular interactions and functions of IL-32. <i>J Leukoc Biol</i> 109 , 143-159 (2021).
1199 1200	88.	Ribeiro-Dias, F. & Oliveira, I.B.N. A Critical Overview of Interleukin 32 in Leishmaniases. <i>Front Immunol</i> 13 , 849340 (2022).
1201 1202	89.	Choi, J.D. <i>et al.</i> Identification of the most active interleukin-32 isoform. <i>Immunology</i> 126 , 535-542 (2009).
1203 1204	90.	Wallimann, A. & Schenk, M. IL-32 as a potential biomarker and therapeutic target in skin inflammation. <i>Front Immunol</i> 14 , 1264236 (2023).

1205 1206	91.	Moulik, S. <i>et al.</i> Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis. <i>Clin Infect Dis</i> 66 , 404-410 (2018).
1207 1208	92.	Sundar, S. & Rai, M. Laboratory diagnosis of visceral leishmaniasis. <i>Clin Diagn Lab Immunol</i> 9 , 951-958 (2002).
1209 1210 1211	93.	de Bruijn, M.H. & Barker, D.C. Diagnosis of New World leishmaniasis: specific detection of species of the Leishmania braziliensis complex by amplification of kinetoplast DNA. <i>Acta Trop</i> 52 , 45-58 (1992).
1212 1213 1214	94.	Celeste, B.J., Angel, S.O., Castro, L.G., Gidlund, M. & Goto, H. Leishmania infantum heat shock protein 83 for the serodiagnosis of tegumentary leishmaniasis. <i>Braz J Med Biol Res</i> 37 , 1591-1593 (2004).
1215 1216 1217 1218	95.	de Oliveira, A.P. <i>et al.</i> Comparison of flow cytometry and indirect immunofluorescence assay in the diagnosis and cure criterion after therapy of American tegumentary leishmaniasis by anti-live Leishmania (Viannia) braziliensis immunoglobulin G. <i>J Immunol Methods</i> 387 , 245- 253 (2013).
1219 1220	96.	Mao, S., Zhang, Y., Seelig, G. & Kannan, S. CellMeSH: probabilistic cell-type identification using indexed literature. <i>Bioinformatics</i> 38 , 1393-1402 (2022).
1221 1222 1223	97.	Dos Santos, J.C. <i>et al.</i> Cytokines and microbicidal molecules regulated by IL-32 in THP-1- derived human macrophages infected with New World Leishmania species. <i>PLoS Negl Trop</i> <i>Dis</i> 11 , e0005413 (2017).
1224		
1225		